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Résumé 
Depuis une décennie, l'industrie pharmaceutique s'intéresse de très près à la synthèse de 
principes actifs constitués de peptides. Ces composés ont l'avantage d'être hautement 
spécifiques, présentent de faibles problèmes toxicologiques et s'accumulent peu dans les 
tissus. Cependant, il existe un réel défi pour les sociétés de mettre au point des synthèses 
peu couteuses, moins polluantes et plus propres. Une synthèse peptidique par voie 
enzymatique serait une alternative. La transglutaminase (TGase) enzyme a Ca2+ dépendance 
qui catalyse le transfert d'un groupement glutamyle d'un donneur acyl, la glutamine à un 
accepteur d'acyle, généralement une lysine, semblerait être un candidat idéal dans cette 
approche. Cette enzyme catalyse la formation de la liaison ami di que entre les aminoacides 
et les peptides et fonctionne dans l'eau de façon quasi-irréversible. Les mimes de TGase 
sont prometteuses dans ce domaine de recherche. Dans ce type de projet, le développement 
de méthodes de détection de l'activité TGase des mutants est d'importance. 
Dans ce travail sera présenté le développement de deux nouvelles méthodes fluométriques 
à haut débit pour la détection de l'activité de la TGase. Ces méthodes présentent de 
nombreux avantages: elles sont tout d'abord très sensibles à faibles concentration en 
enzyme et substrats. Ces méthodes sont reproductibles et peuvent être utilisées dans des 
milieux biologiques plus complexes (lysat). 
Le premier test est basé sur la mesure fluorométrique de l'activité de la TGase et a été 
validé sur la transpeptidation d'un substrat donneur préalablement synthétisé contenant une 
partie N-terminale fluorophore avec un accepteur (une amine biotynilée). Après traitement 
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avec la TGase, le mélange est fixé à une streptavidine immobilisée et l'activité de la TGase 
est mesurée par l'augmentation du signal de fluoresence. 
Le second test est basé sur l'observation du phènoméne de FRET (définie comme un 
transfert d'énergy non radiative suite à une interaction dipole-dipole entre deux molécules 
fluorescentes) suite à la ligation par la TGase d'un donneur acyle marqué avec le 
fluorophore Tokyo Green à une amine primaire marquée avec la 7-hydroxy-coumarine. 
La synthèse des substrats, l'optimisation des tests et leurs applications dans l'étude de 
l'activité de la TGase et leurs possibles applications dans des criblages à haut débit sont 
présentées dans ce mémoire. 
Mots clés: Transglutaminase, FRET, fluorimétrie, enzyme, cinétique, synthèse sur support 
solide, lysat, criblage à haut débit. 
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Abstract 
During the last decade, interest in the synthesis of peptides as drugs has grown, due to their 
high specificity, low toxicology problems, and minimal accumulation in tissue. 
Environmentally sound economical synthesis of peptides represents a challenge considering 
the limitation of CUITent chemistry. Enzymatic peptide synthesis may serve as an alternative 
for efficient peptide synthesis. Transglutaminase (TGase) is a Ca2+ dependent enzyme that 
catalyzes the transamidation of an acyl donor glutamine to an acyl acceptor, lysine. This 
enzyme represents as interesting candidate for peptide synthesis, because it already 
catalyzes amide bond formation between amino acids and peptides, in aqueous solution. 
Methods for the detection of mutant TGase activity are needed to study this enzyme for 
peptide synthesis. 
The present study describes the development of two new high-throughput fluorometric 
methods for the detection of TGase activity. These methods are sensitive at low 
concentration of enzyme and substrate. They are also reproducible and effective in 
biological media expressing enzyme (lysate). 
The first assay is based on the fluorometric measurement of TGase activity. 
Transpeptidation involves an amide donor substrate possessing an N-terminal fluorophore 
moiety and an acceptor amine substrate containing biotin. After treatment with TGase, the 
mixture is fixed to immobilized streptavidine, the resin is washed and TGase activity is 
monitored by the increase of fluorescence signal. 
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The second assay is based on the observation of the FRET (Fluorescence Resonance 
Energy Transfer) effect upon ligation by TGase of a donor acyl substrate labelled with the 
fluorophore Tokyo Green to a primary amine labelled with 7-hydroxycoumarin. 
The synthesis of organic substrates and assay optimization have been perforrned to study 
TGase activity. 
Key Words: transglutaminase, FRET, fluorometry, enzyme, kinetics, solid phase synthesis, 
lysate, high-through put screening, quench. 
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CHAPTERI 
INTRODUCTION 
Chapter 1 2 
1.1 Peptides 
1.1.1 Introduction 
A peptide is a molecule formed from the coupling of two or more a-amino acids via an 
amide bond resulting from the condensation of a carboxylic group of one and the amino 
group of the other. Peptides containing more than 50 amino acids are called proteins. 
Peptides play an important role in regulating many physiological processes, and can be 
used in various treatments for diseases such as the peptide insulin, which is used to treat 
diabetes. 
1.1.2 Peptides as Drugs 
Peptides represent promising candidates for drug discovery due to their high specificity, 
high affinity, low toxicity, and low accumulation in tissues. The first peptide based drug to 
be administered therapeutically was insulin. 1 To date, insulin remains one of the most 
successful peptide based drugs with insulin sales of $ 7 billion (US) in 2005, and expected 
to reach $ 14 billion (US) by 2010.2 
Solution phase synthesis was the method originally used for making peptides; however, this 
method presented many problems involving purification, solubility as the size of the 
peptide grew, reaction times, and low yields. In 1963, a new strategy for peptides synthesis, 
so called solid-phase peptide synthesis (SPPS) was pioneered by Bruce Merrified,3 and had 
a great impact on the chemistry for making peptides by overcoming the problems cited 
above. Five years later, the sol id phase synthesis of oxytocin, 4 and diamino oxytocin were 
reported.5 In fact, this method brought a 20-30 fold increase in the number of analogues 
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that could be synthesized compared to the solution method. The solid phase technique has 
become the most commonly used process for peptide synthesis, moreover, solid-phase 
chemistry has established itself as a useful tool in the field of organic synthesis. Bruce 
Merrifield was awarded the chemistry Nobel Prize in 1984 for the development of a simple 
and ingenious method for obtaining peptides and proteins, his original paper is the 5th most 
highly cited paper in the Journal of the American Chemical Society.3 
The SPPS method has become commonplace for research in drug discovery.6 Over the last 
decade, investment of the pharmaceutical industry in peptide-based therapeutics has 
expanded, prompted by the advances in the understanding of the genetics of diseases and 
drug delivery, as weIl as developments in peptide synthesis. The global market of 
therapeutic peptides in 2007 was valued at around $1 billion (US), and is predicted to 
significantly increase over the next decade.7 In fact, interest in peptide drugs has recently 
intensified with the approval of the peptide-based drug Fuzeon (T-20) an anti-HIV 
treatment by the Roche Company. Peptides are currently being developed for therapeutic 
applications such as, allergy, asthma, cancer, and diabetes. 
1.1.3 Limitations 
To date, compared with the total number of drugs that have been delivered to market, 
peptide based-drugs are considered marginal. As articulated by pioneers in the field, 7 the 
key development of peptides as drugs is contingent on the following facts: 
Improvement in manufacturing to increase yields and reduce costs. 
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Enhanced synthesis of diverse peptide analog libraries to screen agoni st drug 
targets. 
Modification of peptides with non-natural amino acids to increase stability. 
In fact, in spite of the advantages reported above, there are many issues facing this field of 
research that need to be solved in order to gain an increased market for peptides as drugs. 
One of the major problems in this field is the high cost of production of peptide drugs. 
Roche's anti-HIV Fuzeon (T-20), the present synthetic peptide-drug paradigm, costs more 
than $20 000 (US) per pers on a year which restricts its general use. As previously 
mentioned, the solid phase strategy is the method of choice for peptide synthesis. This 
method has two major problems: 
High co st: Coupling reagents and protected ammo acids are expensive, 
commonly used in excess, and rarely recycled 
Pollution: Protection, deprotection and washing steps generate relatively large 
quantities ofwaste per procured product. 
Investment in this field is needed to resolve these two problems: high co st and pollution. 
An increased peptide market demands resolution of these issues to provide affordable 
products in an environmentally friendly manner. 
In order to find an efficient way of synthesizing peptides m low cost and with less 
pollution, the pharmaceutical industry, as weIl as food companies have been investigating 
other methods for large scale peptide synthesis that meet the following criteria: 
Improvement in the time and yield to manufacture peptides. 
Chapter 1 5 
Reduced cost of the synthesis. 
Less pollution. 
Enzymes are available biocatalysts that function in aqueous conditions and more efficiently 
by lowering the activation energy barrier (~G") of a reaction, thus allowing the reaction to 
proceed much faster without affecting the equilibrium of the reaction (Figure 1.1). Industry 
can consider biocatalysts to be a potential strategy for efficient peptide synthesis. The 
proteases have been the principal targeted family of enzyme for amide bond formation 
between a-amino acid residues. 8 
Figure1.1 Difference between enzymatic and non enzymatic reaction 
non enzymatic 
------------- ------------------------------------t- -------Î non enzym.tic 
/ activation energy 
f ------------------------- -----r:~~~~~ 1 
~ _____ ~~~rgï __________ t ________ _ 
enzymatic 
product 
t 
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1.1.4 Proteases 
Proteases occur naturally in aIl organisms and constitute 1-5% of the gene content. These 
enzymes are involved in a multitude of physiological reactions, industrial and 
pharmaceutical applications. 8, 9, 10 Proteases can also be used as biocatalyst for peptide 
bond formation via a kinetically or thermodynamically controlled approach. However, in 
thermodynamically controlled approach the hydrolysis of the formed peptide was favoured 
reducing than the yield of the reaction. Il More research was focused in favouring the 
kinetically approach. 12, 13, 14 For example, subtiligase, a double mutant of subtilisin BPN', 
has been shown to have many uses, from the total synthesis of RNase A to the 
semisynthesis of a variety of other proteins via the coupling of esterified peptides onto the 
N-termini ofproteins in aqueous media and in high yield. 15 Moreover, asprgillus proteases 
were found to be efficient for peptide coupling when using the carbamoyl ester as acyl 
donor. 14 The two major drawbacks of proteases as peptide biocatalyst are substrate 
specificity and hydrolysis of the growing peptide, which respectively lower the flexibility 
and yields ofthis method. 16 Enzyme transglutaminase (TGase)thus has been pursued as an 
alternative for enzyme-catalyzed peptide coupling. 
1.2 Transglutaminase 
1.2.1 Definition 
Transglutaminase (TGases) are a c1ass of Ca2+ -dependent enzymes that catalyze the cross-
linking of proteins through the formation of isopeptide bonds between reactive lysine and 
glutamine residues in proteins. An aminotransferase enzyme, TGase catalyses the 
transamidation of glutamine-containing proteins with a variety of other primary amine 
Chapter 1 7 
nuc1eophiles(scheme 1.1). 17 The so formed isopeptide bonds exhibit resistance to 
proteolytic degradation as weIl as physical-chemical degradation. 
TGase is widely used in several different industrial products and processes. Advances in 
biotechnology have enabled this enzyme to be developed for processes and have made 
these enzymes a viable option for chemical catalysis. In particular, the microbial TGase 
(MTGase) derived from the Streptoverticillium mobaraense in the fermentation of sorghum 
straw hydrolysates has been used in the food industry for catalyzing the cross-linking of 
many food proteins such as caseins, soybean globulins, gluten, actin, myosins, and egg 
proteins, through the formation of an E-(y-glutamyl)lysine bond. Used as weIl for the 
incorporation of primary amines into proteins, MTGase is notable because it is a calcium 
independent enzyme of low molecular weight, which is smaller than of other known 
TGases. 18, 19, 20 Efforts continue to focus on identifying novel and alternative microbial 
sources for production of TGase analogs with greater substrate specificity and enhanced 
utility in (iso) peptide synthesis. 
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Scheme 1.1 Transglutaminase Catalyzed Reactions 
Isopeptide bond formation 
o \. H.N 
X/"y'"" · 
HN "', Il ~ GIn 0 Lys 
°X H TGase "" /yN ------1.~ HN "'" Il ~ 0 o 
y-Glu-Lys 
Primary amide synthesis 
o \. X + H2NR 111111/"y'NHz 
HN "', Il ~ GIn 0 
__ T_G_as_e_---I.~ "X~."' 
~ 0 
Amide hydrolysis 
°X\ 
111111. /"y'NH2 + 
HN "',. Il ~ GIn 0 
TGase 
1,2.2 Mechanism of action 
TGase follows a modified "Ping-Pong" mechanism described by Folk, J in 1969 (Figure 
1.2),21 involving two steps, acylation followed by a deacylation. 
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• Acylation step: 
The acyl donor is bound at the active site of the enzyme forming the first Michaelis 
complex ready for the acylation step. 
The catalytic cysteine thiol attacks the y-carboxamide group of the donor substrate 
(glutamine residue), forming the acyl-enzyme intermediate and releasing one equivalent of 
ammonia.22 
• Deacylation step: 
When the acyl-enzyme intermediate is formed, a competition occurs between hydrolysis 
with water forming glutamic acid (slow reaction), and the aminolysis reaction of the 
intermediate with lysine forming an isopeptidic bond or with a primary amine forming an 
amide bond. 
Figure 1.2: Modified Ping-Pong Mechanism ofTGase 
RC(O)NHR2 
E-SH 
~ RJ~ &~ 
..:s 
E-SC(O)R 
acyl-enzyme intermediate 
E .RC(O)NHR1 
-SH 
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The Keillor laboratory has studied reactions catalyzed by the guinea pig liver TGase and 
demonstrated that the catalytic mechanism involves general base catalysis by 
characterisation of the transition state using kinetic methods. 22 
The TGases family have been identified from different sources such as bacteria, 
invertebrate, and plants. 23 From mammalians, a total of eight different TGase enzymes 
have been identified (Table 1.1): 
• Tissue transglutaminase (TG2): 
Full length human TG2 is 687 amino acids with a predicted molecular mass of - 77 kDa. 
TG2 is weIl conserved, with human TG2 being 80-90% homologous to bovin, mouse and 
guinea pig TG2. 24 The most studied TGase, TG2 exists in the majority of tissues, 
transcription of TG2 is increased by retionoic acid, it plays a role in the extra-cellular 
matrix development, apoptosis and neural differentiation. 25 Beside having transpeptidation 
activity, TG2 also acts as a kinase, 26 protein disulfide isomerase, and deamidase by the 
deamidation of gliadin peptides thus playing an important role in the pathology of coeliac 
disease. 27 TG2 has also been linked to inflammation, neurodegenerative diseases, 
Huntington's disease, 28 and tumor biology. 29 
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Table 1.1: The transglutaminase (TGase) family. 
Factor XIII Fibrin F13Al 732 (83) Blood clotting and Cytosol, 
stabilizing wound healing extracellular 
factor 
Band 4.2 Erythrocyte EPB42 690 (72) Structural prote in in Membrane 
membrane erythrocytes-no 
prote in activity 
TGase 1 Keratinocyte TGMI 814 (90) Cornified envelope Cytosol, 
TGase assembly membrane in surface epithelia 
TGase 2 Tissue TGase TGM2 686 (80) Cell Cytosol, 
death/ differentiation, nucleus, 
adhesion, matrix membrane, 
assembly cell surface, 
extracellular 
TGase 3 Epidermal TGM3 692 (77) Cornified envelope Cytolsol 
TGase assembly in surface 
epithelia 
TGase 4 Prostate TGM4 683 (77) Semen coagulation Unknown 
TGase in rodents 
TGase 5 TGaseX TGM5 719 (81) Epidermal Nuclear 
differentiation matrix, 
cytoskeleton 
TGase 6 TGase Y TGM6 Unknown Unknown Unknown 
TGase 7 TGase Z TGM7 710 (80) Unknown Unknown 
Source: Journal of investigative dermatology, 2005, 124, 481-492. 
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1.2.3 Physiological transglutaminase 
TGase is implicated in different biological processes, including cell adhesion/o apoptosis/ 1 
formation of the extra cellular matrix/2 blood coagulation.33 Deregulation of 
transglutaminase activity leads to different physiological disorders and diseases.34 
1.2.3.1 Alzheimer's disease 
The formation of the ab normal prote in structures of Alzheimer's disease have been 
suggested to be catalyzed by TGase because insoluble isoforms of TGase colocalized with 
plaques and tangles 30-50 times greater than normal brain tissue.35 
1.2.3.2 Huntington's disease 
Huntington's disease (HD) results from genetically programmed degeneration ofbrain cells, 
called neurons, in certain areas of the brain. Elevated TGase activity has been found in the 
affected areas. The implicated protein, Huntington, has been found to be a good substrate 
for the TG 2 enzyme.36 
1.2.3.3 Celiac disease 
Celiac disease is a digestive disease that damages the small intestine and interferes with 
absorption of nutrients from food. Celiac disease is precipitated by the ingestion of gliadin, 
a proteinaneous component of wheat gluten. The presentation of fragments of gliadin cross-
linked to TG 2 results in antibodies against gliadin, TG 2 and the cross-linked proteins. 
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1.2.3.4 Cataract formation 
A cataract is an opacity that develops in the crystalline lens of the eye or in its envelope and 
may cause blindness. Cataracts are distinguished by a marked elevation of intracellular 
Ca2+, which may act to stimulate TGase activity either directly or indirectly suggesting 
involvement of TGase in cataract formation. 37 
1.2.3.5 Atherosc1erosis 
Atherosc1erosis involves the build-up of a waxy deposit on the inside of blood vessels. 
TGase may play a role in the formation of the atherosc1erotic plaques by catalyzing the 
incorporation of lipoprotein (a) (TGase substrate) into these structures, creating insoluble 
atherosc1erotic tissue. 38 
1.2.4 Transglutaminase structure 
To have a good understanding of the structure-function relation for enzyme activity, it is 
very important to know the three-dimensional crystalline structure of the enzyme. Having 
this structure could help researchers to better understand the enzyme, to design efficient 
inhibitors of the enzyme, and to assess the important domains for the activity of the 
enzyme. 
To date, the structures of four different vertebrate TGases have been resolved: the factor 
XIII TGase furnished the first three-dimensional structure, 39 followed by red sea bream 
fish TGase, 40 human tissue TGase (TGase 2), 41 and the epidermal human TGase. 42 
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In the X-ray structures, the enzyme is composed of a p-sandwich at the N-terminal 
containing the residues Gly-6 to Phe-134, the catalytic a/p core containing the residues 
Asn-l35 to Thr-461, the P l barrel covering residues Arg-472 to Ser-583 and P 2 barrel at 
the C-terminal covering residues Thr-584 to Lys-684. The active site belongs to the 
catalytic a/~ core (composed of a-helices and p-sheets). Conserved among TGases, the 
active site is formed by three residues, a cysteine, a histidine and an aspartic acid. Red sea 
bream TG2 and guinea pig liver TGase share around 80% sequence homology at the active 
site (Figure 1.3).43 
Figure 1.3: Resemblance of the Overall Structure of Factor XIII and Red Sea Bream TG2. 
Il - sandwîch 
FTG 
13 - sandwich 
human factor XIII 
activatior 
peptide 
The red sea bream catalytic triad, composed of Cys-272, His-332 and Asp-355, is similar to 
the active site of the widely studied cysteine proteases. The catalytic residues Cys and His 
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are close enough in proximity to form a hydrogen bond. The calcium ion modifies the 
prote in conformation, providing the active form of the enzyme, which is a complex with 
the metal-ion. From this structural information, we can infer information conceming the 
structure and conformation of substrates. 
1.2.5 Transglutaminase binding 
As mentioned earlier, TGase catalyzes the cross-linking of proteins through the formation 
of isopeptide bonds between the side-chains of lysine and glutamine residues. TGase shows 
very high specificity with respect to the electrophilic substrate, and L- glutamine is usually 
required for enzyme recognition.44 The L-glutamine residue lies usually between the third 
amino acid from the N-terminal and the second amino acid from the C-terminal of the 
peptide substrate. 45 The presence of certain amino acids at the C-terminal as weIl as a 
benzyloxycarbonyl group at the N-terminal facilitate the recognition of the electrophilic 
substrate. For example Cbz-L-Gln-Gly is a good substrate for TGase, and was used as 
starting structure for the designing probes for kinetic studies of TGase. 46 Another peptide 
sequence, which has been demonstrated as a good substrate for TGase is PQPQLPY from 
the gluten protein. This sequence exhibits a high affinity for TGase (Km= 30 uM). 47, 48 
Moreover, the EAQQIVM sequence, from the N-terminal of fibronectin, serves as a TGase 
substrate. 49 
TGase tolerates a wider range of nucleophilic substrates: 46 primary alkylamines, such as 
monoprotected putrescine, and cadaverine. 50 The steric bulk of the nucleophilic substrate 
may limit the acylation step. 
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1.3 Aim of the Project 
The general goal of this research project is to develop novel TGases that are capable of 
efficiently catalyzing peptide coupling for economical and environmentally sound peptide 
synthesis. Specifically, this project aims to develop a series of new assays for high-through 
put detection of TGase activity. These assays take advantage of the sensitivity of 
fluorescent probes and are designed to be flexible for studying a variety of TGase mutants. 
Methods for monitoring TGase activity, either in its purified form or within complex 
solutions, are fundamental for the study of TGase and for research towards modifying its 
activity. The Keillor group has previously reported assays for measuring the potency of 
TGase, by monitoring enzyme-catalyzed release of a chromophoric anilide, 51 p-nitrophenol 
22 or 7-hydroxycoumarin leaving group attached to the electrophilic substrate. 52 Although 
sensitive, these methods have the inherent disadvantage of requiring the measurement of a 
chromophoric product or leaving group. Assays that detect released ammonia from amide 
donor substrates 53-55 may provide better mechanistic insight into the enzyme activity than 
those which measure release of a1cohols from activated ester substrates. Assays detecting 
the formation of the acyl-enzyme intermediates have been complemented by those that 
measure the formation of the final product. Recently, two very sensitive methods that detect 
the formation of isopeptidic bonds were reported. Both are based on the increase of 
fluorescence of a dans yI group on the acceptor and donor substrates. In the first case, the 
fluorescence increases as a result of 1t-stacking of the two dansyl moieties after ligation 56 
and in the second case as a result of inclusion within the hydrophobic environment of 
casein. 57 These assays detect the native transamidation reaction. The nature of these assays, 
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however, is not compatible with the wide variation in the structural characteristics of the 
substrates. An assay for in situ TGase activity measurements based on protein biotinylation 
has also been developed. In this method human n~uroblastoma cells were preincubated 
with 5-(biotinamido) pentylamine, the cells were lysed and the homogenate was added to a 
microtiter plate. By addition of horseradish peroxidase conjugated streptavidin and 0-
phenylenediamine dihydrochloride the presence of proteins into which 5-(biotinamido) 
pentylamine had been incorporated was detected by measuring the absorbance at 492 nm. 
The activity of TGase in situ was ca1culated as percentage of basal activity.58 As it relies on 
native protein as the acyl donor substrate, it precludes modification of the acyl donor 
substrate. Therefore, while all these methods are useful to characterize the wild type 
enzyme or for screening inhibitors, they are not suitab1e for screening TGase reactivity 
toward unnatural substrates. The development of two new high through-put assays for 
screening mutant TGases are described herein: 
'" A fluorometric assay for the detection of transglutaminase activity: 
This method is based on the high affinity of biotin to the streptavidin protein. The idea is to 
detect the increase of fluorescence featuring transpeptidation of a donor substrate 
containing N-terminal fluorophore moiety with an acceptor amine substrate containing 
biotin. After treatment with TGase, the mixture is affixed to streptavidin beads and TGase 
activity is monitored by the increase of the fluorescence signal. The optimization of this 
assay and its application in studying TGase activity will be described. 
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./ A continuous FRET based assay for transglutaminse activity: 
Fluorescence resonance energy transfer (FRET), is an interaction of two fluorophores, in 
which an excited-state donor molecule transfers energy nonradiatively to an acceptor 
chromophore. A FRET -based assay for detection of ligation of a don or amine fluorophore 
moiety with an acceptor su~strate containing another fluorophore has been designed. After 
treatrnent with TGase, the activity is monitored by decrease in emission of the donor 
fluorophore and concomitant increase of the acceptor fluororophore signal. 
These assays were designed to meet two major criteria: 
• High sensitivity: in order to detect activity of pure TGase and TGase in lysate. 
• High throughput: in order to test a large number of mutants in a short time. 
Moreover, these assays have the advantage of detecting the E-(y-glutaminyl) lysinyl bond 
formed upon ligation catalyzed by the pure enzyme, and may be suitable for high-through 
put screening of TGase activity in lysate. 
Chapter 1 19 
1.5 References 
1- F. G. Banting, C. H. Best., The internaI secretion of the pancreas. J, Lab. Clin. 
Med. 1922, 7, 251-256. 
2- http://www.metabolic.com.aulfiles/SXH7P6WR YW IUpdateOralPeptideDelivery 
Platform_20Sept2007.pdf. 
3- R. B. Merrifield, Solid Phase Peptide Synthesis. 1. The Synthesis of a 
Tetrapeptide. J Am. Chem. Soc. 1963,85,2149-2154. 
4- Manning, M., Synthesis by the Merrifield method of a protected l10napeptide 
amide with the ami no acid sequence of oxytocin. J Am. Chem. Soc. 1968, 90, 
1348-1349. 
5- H. Takashima, V. Du Vigneaud, R. B. Merrifield, Synthesis of deaminooxytocin 
by the solid phase method. J Am. Chem. Soc. 1968, 90, 1323-1325. 
6- A. Loffet., Peptides as Drugs: 1s There a Market? J. Peptide Sei. 2002,8, 1-7. 
7 - http :/www.in-pharmatechnologist.com/news/ng.asp?n=5 72 90-peptide-market-
finally. (See Annex page 86). 
8- U. C. Banerjee , R. K. Sani, W. Azmi, R. Soni., Thermostable alkaline protease 
from Bacil/us brevis and its characterization as a laundry detergent additive. 
Pro cess Biochem. 1999,35,213-219. 
9- R. Gupta, Q. K. Beg, P. Lorenz., Bacterial alkaline proteases: molecular 
approaches and industrial applications. Appl Microbiol Biotechnol. 2002, 59, 15-
32. 
Chapter 1 20 
10- H. Ishikawa, K. Ishimi, M. Sugiura, A. Sowa, N. Fujiwara., Kinetics and 
mechanism of enzymatic hydrolysis of gelatin layers of X-ray film and release of 
silver particles. J. Fermentation. Bioeng. 1993, 76, 300-305. 
11- M. Lobell, M. P. Schneider., Pronase catalysed peptide syntheses. J. Chem. Soc. 
Trans. 1, 1998, 319-325. 
12- W. C-H, G. M. Whitesides., Enzynles in synthetic organic chemistry ( pergamOl1, 
oxford). 1994,46-59. 
13- D. Kumar . T. C. Bhalla., Microbial proteases in peptide synthesis: approaches 
and applications. Appl Microbiol Biotechnol. 2005, 68, 726-736. 
14- T. Miyazawa, M. Hiramatsu, T. Murashima, T. Yamada., Utilization of Proteases 
from Aspergillus Species for Peptide Synthesis via the Kinetically Controlled 
Approach. Biocatal. Biotransfor. 2003, 21, 93-100. 
15- T. K. Chang, D. Y. Jackson, J. P. Bumier, J. A. Wells., Subtiligase: A tool for 
semisynthesis ofproteins. Proc. Natl. Acad. Sei. USA. 1994,91,12544-12548. 
16- M. Thomlann, S. Thust, Hans-Jorg, Hofmann, F. Bordusa., Protease-Catalyzed 
Hydrolysis of Substrate Mimetics (Inverse Substrates): A New Approach Reveals 
a New Mechanism. Biochemistry. 1999, 38, 6056-6062. 
17- T. Ohtsuka, A. Sawa, R. Kawabata, N. Nio, and M. Motoki., Substrate 
Specificities of Microbial Transglutaminase for Primary Amines. J. Agric. Food. 
Chem. 2000,48,6230-6233. 
18- M. Motoki, K. Seguro., Transglutaminase and its use for food processing, Trends 
Food. Sei. Technology. 1998, 9, 204-210. 
Chapter 1 21 
19- Z. Pietrasik, E. C. Y. Li-Chan., Binding and texturaI properties of beef gels as 
affected by protein, k-carrageenan and microbial transglutaminase addition. Food 
Res. Int. 2002, 35, 91-98. 
20- P. C. Lorenzen, H. Neve, A. Mautner, E. Schlimme., Effect of enzymatic cross-
linking of milk proteins on functional properties of set-style yoghurt , Int. J. Dairy 
Technol. 2002, 55, 152-157. 
21- J. E. Folk., Mechanism of action of guinea pig liver transglutaminase. VI. order of 
substrate addition. J. Biol. Chem. 1969,244,3707-3713. 
22- A. Leblanc, C. Gravel, J. Labelle, J.W. Keillor., Kinetic studies of guinea pig 
liver transglutaminase reveal a general-base-catalyzed deacylation mechanism. 
Biochemistry. 2001,40, 8335-8342. 
23- M. D. Mea, D. Caparr6s-Ruiz, 1. Claparols, D. Serafini-Fracassini, J. Rigau., 
AtPnglp. The First Plant Transglutaminase. Plant Physiol. 2004, 135,2046-2054. 
24- V. Gentile, M. Saydak, E. A. Chiocca, O. Akande, P. J. Birckbichler, K. N. Lee, 
J. P. Stein, and P. J. Davies., Isolation and characterization of cDNA clones to 
mouse macrophage and human endothelial cell tissue transglutaminases. J. Biol. 
Chem. 1991, 266, 478-483. 
25- R. B. Maccioni, N. W. Seeds., Transglutaminase and neuronal differentiation. 
Mol. Cel!. Biochem. 1986,69, 161-168. 
26- S. Mishra, L. J. Murphy., Tissue transglutaminase has intrinsic kinase activity: 
identification of transglutaminase 2 as an insulin-like growth factor-binding 
protein-3 kinase. J. Biol. Chem. 2004, 279, 23863-23868. 
Chapter 1 22 
27- W. Sakly, V. Thomas, G Quash, S, El Alaoui., A role for tissue transglutaminase 
in alpha-gliadin peptide cytotoxicity. Clin. Exp. Immunol. 2006, 146, 550-558. 
28- M. V. Karpuj, M. W. Becher, L. Steinman., Evidence for a role for 
transglutaminase III Huntington's disease and the potential therapeutic 
implications. Neurochem. Int. 2002, 40, 31-36. 
29- J. S. Palumbo, K. A. Barney, E. A. Blevins, M. A. Shaw, A. Mishra, M. J. Flick, 
K. W. Kombrinks, K. E. Talmage, M. Souri, A. Ichinoseand J. L. Degen., Factor 
XIII transglutaminase supports hematogenous tumor cell metastasis through a 
mechanism dependent on natural killer cell function. J. Thrombosis. Haemostasis. 
2008,6,812-819. 
30- Gentile, V. Thomazy, M. Piacentini, L. Fesus, P. J. A. Davies., Expression of 
tissue transglutaminase in balb-C 3T3 fibroblasts: effects on cellular morphology 
and adhesion. J. Cell. Biol. 1992, 119,463-474. 
31-S. Oliverio, A. Amendola, F. Di Sano, M.G. Farrace, L. Fesus, Z. Nemes, L. 
Piredda, A. Spinedi, M. Piacentini., Tissue Transglutaminase-dependent 
posttranslational modification of the retinoblastoma gene product III 
promonocytic cells undergoing apoptosis. Mol. Cell. Biol. 1997, 17,6040-6048. 
32- D. Aeschlimann, O. Kaupp, M. Paulsson, Transglutaminase-catalyzed matrix 
cross-linking in differentiating cartilage., identification of osteonectin as a Major 
glutaminyl substrate. J. Cell Biol. 1995, 129, 881-892. 
Chapter 1 23 
33- Thung-S. Lai, Thomas F. Slaughter, Keith A. Peoples, and Charles S. Greenberg., 
Site-directed mutagenesis of the ca1cium-binding site of blood coagulation factor 
XIIIa. J Biol. Chem. 1999,274, 24953-24958. 
34-S-Y. Kim, T. M. Jeitner, P. M. Steinert., Transglutaminases In disease. 
Neurochem. Int. 2002,40,85-103. 
35- S. Kim, Philip Grant, Jeung-Hoon Lee, Harish e. Pant, and Peter M. Steinert., 
DifferentiaI expression of multiple transglutaminases in human brain. Increased 
expression and cross-linking by transglutaminases 1 and 2 in alzheimer's disease. 
J Biol. Chem. 1999,274,30715-30721. 
36- M. V. Karpuj, M. W. Becher, L. Steinman., Evidence for a role for 
transglutaminase In Huntington's disease and the potential therapeutic 
implications. Neurochem. Int. 2002, 40, 31-36. 
37- J. E. Folk, J. S. Finlayson., The epsilon-(gamma-glutamyl) lysine crosslink and 
the catalytic role oftransglutaminases. Adv. Protein Chem. 1977,31, 1-133. 
38- M. A. Romanic, A. J. Arleth, R. N. Willette, E. H. Ohlstein., Factor XIII a cross-
links lipoprotein(a) with fibrinogen and is present in human atherosclerotic 
lesions. Circ. Res. 1998,83,264-269. 
39- V. e. Yee, L.e. Pedersen, 1. L. Trong, P. D. Bishop, R.E. Stenkamp, D. e. 
Teller., Three-Dimensional Structure of a Transglutaminase: Human Blood 
Coagulation Factor XIII. Proc. Nat. Acad. Sei. U.S.A. 1994, 91, 7296-7300. 
Chapter 1 24 
40-K. Noguchi, K. Ishikawa, K. Yokoyama, T. Ohtsuka, N. Nio, E. Suzuki Crystal 
Structure of Red Sea Bream Transglutaminase. J. Biol. Chem. 2001,276, 12055-
12059. 
41- S. Liu, R. A. Cerione, J. Clardy., Structural basis for the guanine nucleotide-
binding activity of tissue transglutaminase and its regulation of transamidation 
activity. Proc. Nat. Acad. Sei. US.A. 2002,99,2743-2747. 
42- B. Ahvazi, K. M. Boeshans, P. M. Steinert., Crystal Structure of 
Transglutaminase 3 in Complex with GMP: structural basis for nucleotide 
specificity. J. Biol. Chem. 2004,279,26716-26725. 
43- T. Ohtsuka, M. Ota, N. Nio, M. Motoki., Comparison of substrate specificities of 
transglutaminases using synthetic peptides as acyl donors. Biosci., Biotechnol. 
Biochem. 2000,64,2608-2613. 
44- J. E. Folk, P. W. Cole., Transglutaminase: mechanistic features of the active site 
as determined by kinetic and inhibitor studies. Biochim. Biophys. Acta. 1966, 122, 
244-264. 
45- J. E. Folk, S. 1. Chung., Transglutaminase. Methods in Enzymology. 1985, 113, 
358-375. 
46- J. E. Folk., Mechanism and basis for specificity of transglutaminase-catalyzed 
epsilon-(gamma-glutamyl)-lysine bond formation. Adv. Enzymol. Relat. Areas 
Mol. Boil. 1983, 54, 1-56. 
Chapter 1 25 
47- K. Choi, M. Siegel, J. L. Piper, L. Yuan, E. Cho, P. Stmad, B. Omary, K. M. 
Rich, C. Khosla., Chemistry and biology of dihydroisoxazole derivatives: 
selective inhibitors ofhuman transglutaminase 2. Chem. Biol. 2005, 12,469-475. 
48- F. Hausch, T. Halttunen, M. Maki, C. Khosla., Design, synthesis, and evaluation 
of gluten peptide analogs as selective inhibitors of human tissue transglutaminase. 
Chem. Biol. 2003, 10, 225-231.. 
49- H. Sato, N. Yamada, N. Shimba, y. Takahara., Unique substrate specificities of two 
adjacent glutamine residues in EAQQIVM for transglutaminase: identification 
and characterization of the reaction products by electrospray ionization tandem 
mass spectrometry. Anal. Biochem. 2000,281, 68-76. 
50- Mary Lynn Fink, Yvonne Y. Shao, Gilbert J. Kersh., A fluorometric, high-
performance liquid chromatographic assay for transglutaminase activity. Anal. 
Biochem. 1992,201, 270-276. 
51-P. de Macédo, C. Marrano, J.W. Keillor., A direct continuous spectrophotometric 
assay for transglutaminase activity. Anal. Biochem. 2000, 285, 16-20. 
52- S. M. F. G. Gillet, J. N. Pelletier, J. W. Keillor., A direct fluorometric assay for 
tissue transglutaminase. Anal. Biochem. 2005, 347, 221-226. 
53- A. R. Bames, J. K. Sugden., Comparison of colourimetric methods for ammonia 
determination. Pharm. Acta Helv. 1990,65,258-261. 
54- S. Sheng, J. J. Kraft, S. M. Shuster., A specific quantitative colorimetric assay for 
L-asparagine. Anal. Biochem. 1993,211,242-249. 
Chapter 1 26 
55- N. Day, J. W. Keillor., A continuous spectrophotometric linked enzyme assay for 
transglutaminase activity. Anal. Biochem. 1999,274, 141-144. 
56- T. M. Jeitner, H. -L. Fuchsbauer, J.P. Blass, AJ.L. Cooper, A sensitive 
fluorometric assay for tissue transglutaminase. Anal. Biochem. 2001, 292, 198-
206. 
57- A. Case, J. Ni, L.-A. Yeh, R.L. Stein., Development of a mechanism-based assay 
for tissue transglutaminase-results of a high-throughput screen and discovery of 
inhibitors. Anal. Biochem. 2005,338,237-244. 
58- J. Zhang, M. Lesort, R. P. Guttmann, G. V. W. Johnson., Mudulation of the in 
situ activity of tissue transglutaminase by calcium and GTP. J. Biol. Chem. 1998, 
273,2288-2295. 
Chapter2 
CHAPTER2 
A fluorometric assay for the detection of 
transglutaminase activity. 
27 
Chapter 2 28 
2.1 Introduction 
The attachement of biotin to various chemical sites, so called biotinylation, can be used as 
an important laboratory technique for studying various processes, inc1uding protein 
localization, protein-protein interactions, DNA transcription and replication. 59, 60, 61 Biotin 
binds tightly to the tetrameric protein avidin (as weIl as streptavidin and neutravidin), with 
a dissociation constant Kd in order of 10- 15 mol/L. In different biotechnological 
applications, biotin is added to a molecule of interest for fixation to a supported 
streptavidin, and subsequent measurements of activity. 
Herein, we present a discontinuous assay with synthetic donor and acceptor substrates. In 
the as say reaction, TGase catalyzes the formation of a conjugate between a synthetic acyl-
donor substrate, bearing the Tokyo Green fluorophore, 62 and an amine acceptor substrate 
bearing a biotin group. The resulting biotinylated fluorophore-Iabelled product is then 
trapped with immobilized streptavidin. Unreacted substrates are removed by washing and 
subsequent fluorescent measurement allows sensitive detection of activity. For ease of 
application, the method was adapted to use in 96-well microtiter plates. This assay is highly 
sensitive, allowing detection of as little as 8.25 IlU of TGase activity from a sample of 
purified enzyme, yet it is also sufficiently flexible to be used for detection of as little as 91 
mU of TGase activity in a complex biological sample. While this assay was validated using 
native-like substrates, both substrates can be readily modified to allow screening for TGase 
reactivity toward unnatural substrates (Figure 2.1). 
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Figure 2.1: Model of streptavidin beads assay of detection of TGase activity. 
Excitation 495 nm 
" Emission 535 nm 
~ n.., 
Cl 
HNÀO " 
streptavidin 
"----> 
2.2 Materials and methods 
2.2.1 Enzyme preparation 
Recombinant guinea pig liver TGase was over-expressed and purified from Escherichia 
coli as previously published. 63 The purified TGase solution used in all assays had a 
specific activity of 14 U/mg in 25 mM Tris-acetate (pH 7) according to the 
hydroxamate activity assay, 64 in which Cbz-Gln-Gly and hydroxylamine are used as 
acyl-donor and acyl-acceptor substrates respectively. 
2.2.2 Preparation of crude bacterial lysate 
First day: For expression of recombinant guinea pig liver TGase, 4 mL of Terrifie Broth 
(TB), 65 containing 100 !-tg/mL ampicillin (Amp) and 30 !-tg/mL chloramphenicol (ChI) was 
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inoculated with E. coli XLI-Blue harbouring the plasmids pDnaKJ (Chl-resistant) and 
pQE-32 TGase (Amp-resistant). E. coli XLI-Blue harbouring pDnaKJ only, inoculated in 
TB + ChI, was used as a control cell line not expressing TGase. All cultures were 
incubated for 17 h at 37 OC with shaking at 240 RPM in a C25 Incubator Shaker (New 
Brunswick Scientific, Edison, NJ. USA). 
Second day: Aliquots of 1.5 JlL of pre-culture were used to inoculate 1.5 mL of fresh 
TB medium containing the appropriate antibiotics in wells of a 48-well plate (maximum 
volume: 6 mL/weIl) at a ratio of 1/20. The bacteria were propagated at 37 OC with 
shaking at 240 RPM. When the OD (600 nm) reached approximately 0.5, over-
expression of TGase was induced by addition of IPTG to a final concentration of 1 mM. 
The plate was then incubated at 28 oC with shaking at 800 RPM for 20 hrs in a Titer 
Plate Shaker (Lab-Line Instruments, Inc.). 
Third day: The plate was centrifuged for 30 min at 4°C and 3000 RPM (Allegra ™ 6R 
Centrifuge). The supernatant was discarded. The bacterial cell pellets were stored at -
80 oC for 10 min, thawed, resuspended in 200 JlL of CelLytic ™ B cell lysis reagent 
(Sigma) and incubated at 28 oC for 20 min. The crude bacterial lysates thus obtained 
and used for subsequent tests were determined by hydroxamate test to show an activity 
of~18 V/mL 
2.3 Synthesis and kinetics for acyl donor substrate 
Recognition of the acyl donor in vivo is restricted to the y-carboxyamide of glutamine 
within a relatively restricted subset of sequence contexts. The tirst peptide sequence of 
interest was Gln-Gly. In fact, it was demonstrated that the Cbz-Gln-Gly is a substrate 
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for the TGase enzyme. 44 Different fluorophores (dansyl, fluoresecein, carboxy Tokyo 
Green) were attached at the N-terminal of Gln-Gly, and none of these peptides were 
recognized by the enzyme, as initially suggested by the molecular modeling study by 
Chica et al. 66 This was attributed to the importance of the N-terminal group for 
recognition by the TGase enzyme. Furthermore, the C-terminal group exhibits opposing 
properties, in that it is less tolerated as a recognition site by the enzyme. The alternative 
tetrapeptide Gln-Leu-Pro-Phe was selected as a known 67 acyl-donor substrate for 
TGase and conjugated to one of three fluorophores - Tokyo Green, 62 fluorescein 
isothiocaynate and dansyl - by way of an aminocaproate spacer. Three biotinylated 
amines were also explored as acyl-acceptor substrates for isopeptide bond formation 
with the acyl-donor substrate. 
In order to verify if the identity of the fluorophore affected the extent of productive 
binding of the donor substrate to TGase, acyl-donor substrates 11a-e were prepared by a 
solid phase synthetic strategy (Scheme 2.1). Tokyo Green was chosen as a fluorophore 
(in compound 11a) because it is characterized by a high quantum yield (<1> = 0.93) 62 
and possesses a carboxylate that is suitably disposed to allow peptide coupling. The two 
additional fluorophores, dansyl chloride and fluorescein isothiocyanate, were also tested 
(yielding 11 band 11e, respectively) because they are commercially available and 
equally amenable to coupling reactions. Donor substrates l1a-e were found to have low 
KM values of 28.7 ± 6.1 IlM, 13.1 ± 1.8 IlM, and 72.5 ± 6.0 IlM (Table 2.1), 
respectively, using the DMPDA method. 51 
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scheme 2.1 Solid-phase support synthesis of different acyl donors. 
1) Fmoc-Phe-OH, 0 FmOCHN0o~ HO~ DICI DMF, OoC .. 
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DIEA, DMF, 6h 
1) Fmoc deprotection 
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---------__ .. TG-AC-Gln-Leu-Pro-Phe 
1) Fmoc deprotection 
2) FITC,DIEA, DMF, 6h 
3) TFA: DCM (1:1) 
FTU-AC-Gln-Leu-Pro-Phe 
(11b) 
TG 
HO 
2) TG-OH, EDC'HCI, HOBt, 
DIEA, DMF, 6h 
3) TFA: DCM (1:1) 
1) Fmoc deprotection 
2) Dansyl Chloride, DIEA, DMF, 6h 
3)TFA: DCM (1:1) 
Dansyl-AC-Gln-Leu-Pro-Phe 
(11c) 
S Dansyl 
FTU ..-A NH ~I (\ '-': N" /' \\ 1 
o ~ 
o HO 0 
(11a) 
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Table 2.1: Kinetic constants for TGase with various N-terminal derivative peptides 
substrate 
Dansy-E-Ac-Gln-Leu-Pro-Phe 
aTG-E-Ac-Gln-Leu-Pro-Phe 
aIF -E-Ac-G In-Leu-Pro-Phe 
72.5 ± 6.0 
28.6 ± 6.1 
13.1 ± 1.8 
219 ± 39.6 
282 ± 29.8 
290 ± 14.7 
a TG) 4-Carboxy-Tokyo Green, IF) isocyanate fluorescein, Ac) amino caproyl. 
2.4 Synthesis and kinetics for acyl acceptor substrate 
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Biotinylated amines 16a-c were synthesized by coupling biotin to their corresponding 
diamines 13a-c (Scheme 2.2). The shortest spacer used was 1,5-diaminopentane 13a. 
Tris(ethylene glycol)-1,8-diamine 13b was both longer and more polar, white 2-(2-
amino-ethyldisulfonyl)-ethylamine 13c was of length similar to 13a but contained a 
cleavable disulfide bond. Compounds 16a-c were tested as acceptor substrates using the 
Cbz-L-Glu(O-p-nitrophenyl)Gly assay 23 and found to have KM values of 2.3 ± 0.4 mM, 
11.3 ± 3.7 mM, and 13.6 ± 4.6 mM, respectively (Table 2.2). Thus, the different 
spacers tested aU provided productive binding in the same order of magnitude, 
validating their use in the coupling reaction. 
Table 2.2: Kinetic constants for TGase with various acyl acceptor 
substrate 
16 a 
6b 
16 c 
Km (mM) 
2.3 ± 0.4 
11.3±3.7 
13.6 ± 4.6 
V max (mmol.min-l ) 
43.4 ± 2.4 
4.4 ± 0.6 
9.9 ± 1.7 
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Scheme 2.2: Synthesis of different acyl acceptors 
x= 
(C) s-s 
o 
/S~N~X~NH HCI HCI(1 M) 
)--\ .. IU H 2 ....... ~-~..:....--
HN NH 1 (16): (a), (b), (c) 
2.4.1 Materials 
.... 
TBTU, DIEA 
o 
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(14): (a), (b), (C) 
~OH 
HN~NH 
o 
o 
~~~X'./'NHBo<: 
HN NH 
\\ (15): (a), (b), (c) 
o 
The buffer solution in aIl assays gave a final concentration of 100 mM Tris-HCl (pH 8), 
0.6 mM EDTA, and 10 mM CaCh. The washing buffer solution was composed of 100 
mM sodium phosphate (pH 8), 100 mM NaCl, and 0.1% SDS. Water was purified using 
a Millipore BioCell water purification system. Streptavidin beads (Pierce) were 
supplied as a suspension capable of binding 15-28 Ilg biotinimL of settled resin (a 
capacity corresponding to ~ 1-3 mg biotinylated BSA/mL of resin) on a support of 6% 
crosslinked beaded agarose. 
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2.5 Assay procedure using a purified enzyme 
2.5.1 Methods 
AIl assays were performed in triplicate. Donor substrate 11a, b, or c (10 ilL of 0.6 mM 
stock solution), acceptor substrate 16a, b, or c (10 ilL of 0.6 mM stock solution), 80 ilL 
of buffer solution, and 90 ilL of water were combined in a final volume of 190 ilL. The 
reaction was initiated by addition of 25 Ilg (10 Ill) of purified TGase 63 or an equivalent 
volume of 25 mM tris-acetate assay buffer for the blank. FoIlowing incubation for 30 
min at 25 oC, 10 III of the streptavidin bead suspension was added. The mixture was 
incubated for 30 min at 25 oc. The tubes were centrifuged for 1 min at 1400 RPM 
(micro centrifuge). The supernatant was discarded. The pellets were washed by 
resuspension in washing buffer (200 ilL) and centrifuged as above. The pellets were 
washed twice more, resuspended in washing buffer (100 ilL) and transferred to a 
polystyrene 96-well plate. Enzyme activity was detected using a Perkin Elmer Bio 
Assay Reader (HTS 7000) using Aexc = 485 nm, Aem = 535 nm for substrates 11a and 
11b, and Aexc = 360 nm, Aem = 535 nm for substrate 11c, by measuring the increased 
fluorescence signal relative to the blank. 
Reduction of the disulfide-bridged acyl-acceptor substrate 
Substrates 11a and 16c were incubated for 60 min at 25 oC (30 IlM 11a, 30 IlM 16c, 
100 mM Tris-HCI, 10 mM CaCh, 0.6 mM EDTA, and 350 mU TGase in a total volume 
of 200 ilL), after which 10 ilL of streptavidin bead suspension was added. The mixture 
was incubated for a further 60 min. The tubes were centrifuged for 1 min at 1400 x 
RPM (microcentrifuge) and the supernatant discarded. The resin was washed twice by 
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adding 200 ~L of wash buffer, centrifuging for 1 min at 1400 x RPM (microcentrifuge) 
and discarding the supernatant. Finally the beads were suspended in 1 00 ~L of wash 
buffer for treatment under one of the following conditions: 
1 1 00 ~L of 0.1 M DTT was added, followed by 15 min incubation, centrifugation and 
removal of the supernatant for fluorescence detection. 
2 1 00 ~L of 0.1 M DTT was added, followed by 15 min incubation, and the entire 
mixture was used for fluorescence detection. 
3 1 00 ~L of water was added, followed by centrifugation and removal of the 
supernatant for fluorescence detection. 
4 1 00 ~L of water was added, and the entire mixture was used for fluorescence 
detection. 
2.5.2 Results and discussion 
In our fluorescent assay for TGase, using synthetic donor and acceptor substrates, the 
formation of a conjugate between a fluorescent acyl-donor substrate and an amine acceptor 
substrate bearing a biotin group was catalyzed by TGase. The resulting biotinylated 
fluorophore-Iabelled product was trapped with immobilized streptavidin. 
• Assay sensitivity with different acyl acceptors 
To evaluate the effect of the acceptor substrate spacer on assay sensitivity, acyl donor 
substrate 11a was incubated with acyl acceptor substrates 16a-c, respectively, at final 
concentrations of 30 JlM, in the presence or absence of TGase (Figure 2.2). The 
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acceptor substrates 16a-c gave different levels of fluorescence that did not correlate 
with their KM values. For example, the highest and lowest fluorescence measurements 
were exhibited by the substrate harbouring the polyethylene glycol 16b and disulfide 
16c spacer, respectively, that exhibited very similar KM values. 
Acceptor substrate 16c gave the highest signal and contains a disulfide spacer, which 
also offered the potential for 'reversible' biotinylation by reductive cleavage of the 
disulfide bond. This allowed us to verify whether quantitation of the fluorescent 
conjugate directly on the streptavidin beads provided a maximum signal or whether 
some loss of fluorescence was suffered. Thus, following enzymatic coupling of the 
donor and acceptor substrates Il a and 16c, trapping on the streptavidin-coated beads 
and washing, reduction using D,L-dithiothreitol (DTT) and separation by centrifugation 
allowed measurement of the released fluorophore in the absence of the beads (Table 
2.3). 
The intensity of the fluorescence measured for the released fluorophore (+DTT, before 
or after centrifugation) was comparable to that measured directly on the beads (-DTT, 
before centrifugation). A low level of fluorescence was apparently released from the 
beads even in the absence of DTT (-DTT, after centrifugation). Nonetheless, 
fluorescence measurement directly on the beads was not significantly hampered and the 
additional steps required to release the fluorophore were not deemed to be justified. As 
compound 16c yielded the highest fluorescence after coupling to the donor substrate 
11a (Figure 2.2), it was retained as the most suitable acceptor substrate for further 
measurements. 
Chapter 2 38 
Figure 2.2: Comparison of assay sensitivity using acyl acceptor substrates 16a-c, which 
differ by their spacer. Substrate lIa was the acyl donor. Results are provided for triplicates. 
The error bars represent the standard deviation from the mean. 
75000 
-:J 
~ 50000 
-->-... 
. Ci) 
c: 
~ 25000 
o 
_ 350 mU TGase 
1 iil Blank 
11a + 16a 11a + 16b 11a + 16c 
Table 2.3: Fluorescence resulting from the coupling of lIa and 16c, measured on 
streptavidin beads or following release. 
Before centrifugation 
Supematant after centrifugation 
a Àex = 485 nm, Àem = 535 nm 
Fluorescence (a.f.uf 
+DTT -DTT 
6.3 X 104 
4.2 X 104 
4.6 X 104 
1.0 X 104 
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• Assay sensitivity with different acyl donors 
To evaluate the effect of the fluorophore on assay sensitivity, acyl-acceptor substrate 
16c was incubated with the acyl-donor substrates 11a-c and purified TGase. Substrate 
lle was shown to be an insufficiently intense fluorophore and was not retained for 
further testing. The substrates lIa and lib showed significant enhancement of signal 
compared to the control, but the fluorescence of the blank for lib was significantly 
higher than that of 11a. Among these acyl donor substrates, 11a gave the best results 
and was therefore chosen for subsquent tests (Figure 2.3). 
Figure 2.3: Assay sensitivity with acyl donor lla-c and acyl acceptor substrate 16c . 
Results are provided for triplicates. The error bars represent the standard deviation from the 
mean. 
75000 
-:::::J 
~ 50000 
-~ 
'ü) 
c: 
jB 25000 
c: 
o 
11a + 16c 
_ 350 mU TGase 
1~IBlank 
11b + 16c 11c + 16c 
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• Limit of detection 
The limit of detection of the assay with respect to TGase concentration was then 
determined using different concentrations of purified TGase with acyl donor lIa and 
acyl acceptor 16c (see Experimental). While as little as 3.3 V..D of purified TGase 
provided a signal that was detectable above the background of the blank, we assess 
conservatively that the minimum amount of enzyme reliably detected corresponded to 
8.25 IJU (Figure 2.4). This is lower than other previously reported limits of detection,48 
making this the most sensitive tissue TGase assay reported to date, to the best of our 
knowledge. 
Figure 2.4: Limit of detection of the assay with respect to TGase concentration. Results are 
provided for triplicates. The error bars represent the standard deviation from the mean. 
15000 
-::J 
~ 10000 
->-
-en 
c: 
JB 5000 c: 
o 
o 3.3 8.25 22.9 330 
TGase (f.tU) 
( 
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2.6 Assay procedure using crude bacteriallysate 
2.6.1 Methods 
AU assays were performed in triplicate. Donor substrate 11a (1 0 ~L of 6 mM stock 
solution), acceptor substrate 16c (1 0 ~L of 6 mM stock solution), 80 ~L of buffer solution, 
and 90 ~L of water were combined in a final volume of 190 ilL. The reaction was initiated 
by addition of 5-10 ilL of crude bacterial lysate expressing TGase, or bacterial lysate void 
of the TGase expression plasmid as a blank. Following incubation for 60 min at 25 oC, a 
fraction of the solution (10 ilL) was added to a mixture of 180 ilL ofwashing buffer and 10 
ilL of streptavidin bead suspension. The mixture was incubated for 30 min at 25 oC, and 
centrifuged for 1 min at 1400 RPM (microcentrifuge). The pellets were washed three times 
as described above, resuspended in washing buffer (100 ilL) and transferred to a 
polystyrene 96-well plate for analysis of enzyme activity by measuring fluorescence 
relative to the blank, as described above. 
2.6.2 Results and discussion 
To be of enhanced practical value, an enzymatic assay should also be amenable to 
detection of activity in complex biological samples. The coupling of acyl donor lIa and 
acyl acceptor 16c was thus undertaken using crude lysate of E. coli expressing 
recombinant TGase, using as a negative control the lysate of E. coli void of the 
expression plasmid. When analyzing TGase activity in complex biological samples, 
assays that measure only the first step of the transamidation may give artificially higher 
activities due to competing hydrolysis of the acyl donor substrate. In contrast to such 
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assays which report the extent of acylation of the enzyme, detection of fluorescence in 
the present assay is a consequence of formation of an amide (Figure 2.5). 
Notably, TGase activity was detected with high sensitivity in lysate (Figure 2.6); 
however, the intensity of signal was not proportional to the amount of lysate used, over 
the Hmited range that was tested. Although more lysate provides more enzyme, 
alternative acceptor amine substrates present in the crude cellular lysate may compete 
with the acceptor substrate 16c, ultimately decreasing the amount of biotinylated 
fluorophore product. Ultimately we found that a 40-fold dilution of lysate in substrate 
solution provided a reliable and reproducible means of detecting low levels of TGase 
activity in crude lysate. 
Figure 2.5: Product 17 formed by TGase ligation of acyl donor 11a and acyl acceptor 16c 
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Figure 2.6: Detection of TGase activity in crude bacterial lysate. Results are provided for 
triplicates. The error bars represent the standard deviation from the mean. 
75000 
-:::l 
~ 50000 
-~ 
"Ci) 
c: 
~ 25000 
o 
2.7 Conclusion 
_+ Lysate 
l;mûÊHH,ill~~;,;1 Blank 
5 Jll 10 /-tl 
Volume of bacteriallysate 
In summary, an as say for the detection of the TGase activity has been developed with 
the highest sensitivity yet reported. This assay has proven to be effective for detection 
using crude bacterial lysate as weIl as purified TGase. Because both donor and acceptor 
substrates are synthetic, we are currently investigating their modification for application 
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to high throughput screening of libraries of mutant TGase having potentially different 
substrate specificity. 
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2.8 Experimental section 
General 
AU solvents used for reactions were purified with solvent filtration systems (Glass 
Contour, Irvine, CA). 4-Carboxy-Tokyo Green was synthesized according to a 
published procedure. 59 Wang resin and amino acids were purchased from Nova 
Biochem except for Fmoc-Gln-OH, obtained from Advanced ChemTech. and Fmoc-e-
aminocaproic acid, obtained from Bachem Chemical. All other reagents were obtained 
from Sigma-Aldrich. lH_ and 13C-NMR spectra were recorded on Bruker NMR 
spectrometers. 
Reactor tubes for solid-phase peptide synthesis were obtained from Alltec Associates 
Inc. and shaking was performed on a reciprocating shaker (SK-300 Jeio Tech). All 
resins were swelled in DMF and washing steps were performed using CH2Ch and DMF 
(EMD Chemicals) using five DMF washes followed by three CH2Ch washes. 
Purification of aIl peptides was performed using a preparative HPLC method. Mass 
spectral data (MS, LCMS) were all obtained using two different solvent systems 
(MeOH/water; acetonitrile/water) at the Centre Régional de Spectrométrie de Masse de 
l'Université de Montréal. 
General procedure for Fmoc deprotection: Wang resin (0.81 mmol/g) purchased 
from Nova Biochem was treated with a mixture of 20% piperidine in DMF, shaken for 
30 min, filtered and washed as described above. Deprotection was verified by positive 
Kaiser test on a sample of a few beads. 68 The level of loading of the amino acid on the 
resin after the first coupling step was used as the resin loading capacity for aIl 
subsequent steps, as determined by spectroscopic measurement of the UV absorbance of 
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the piperidine dibenzofuivaiene adduct. 
Peptide sequence purity was performed on an aliquot of resin using LCMS-MS in two 
differents solvant system: method A: 40-80% acetonitriIe, H20, 0.1 % formic acid, 0.5 
mL! min, À= 214 nm, Agilent LCMSD, ,column: C6 Phenyl, 3H, 50 x 4.6 Gemini. 
Method B: 60-90% MeOH, H20, 0.1 % formic acid, 0.5 mL! min, À= 254 nm, Agilent 
LCMSD, column: C6 Phenyl, 3H, 50 x 4.6 Gemini. 
Kinetics 
Kinetic parameters for aIl donor substrates were determined independently using the 
N,N-dimethyl-1,4-phenylenediamine (DMPDA) method,47 using a range of donor 
substrate concentrations of 0.5 mM to 20 mM and a constant acceptor substrate 
concentration of 20 mM. Kinetic parameters for acceptor substrates were obtained using 
the chromogenic donor substrate, Cbz-L-Glu(O-p-nitrophenyI)Gly,17 using a range of 
acceptor substrate concentrations of 2 mM to 30 mM and a constant donor substrate 
concentration of 0.108 mM (5-foid apparent KM). Initial rates were measured as a 
function of varied substrate concentration and kinetic parameters were determined from 
non-linear regression to the hyperbolic Michaelis-Menten equation. 
Determination of Peptide sequence purity was performed on an aliquot of resin using 
LCMS-MS in two differents solvant system: method A: 40-80% acetonitrile, H20, 0.1 % 
formic acid, 0.5 mL! min, À:::::; 214 nm, Agilent LCMSD, column: C6 Phenyl, 3H, 50 x 
4.6 Gemini. Method B: 60-90% MeOH, H20, 0.1 % formic acid, 0.5 mL! min, À= 254 
nm, Agitent LCMSD, column: C6 Phenyl, 3H, 50 x 4.6 Gemini. 
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Synthesis of the donor substrates. 
Supported Fmoc-L-phenylalaninate 6 
In a 20-mL round-bottom flask, Fmoc-Phe-OH (2.116 g, 7.12 mmol, 8 eq) was 
dissolved in a minimum volume of dry DMF (5 mL) with magnetic stirring, chilled to 0 
oC, treated with DIC (557 ilL, 3.56 mmol, 4 eq), and stirred for 15 min, when a white 
precipitate was observed. The solution was then tiltered through a fritted funnel into a 
20-mL syringe tube equipped with a stopcock and a Teflon tilter containing 2 g of 
Wang resin (0.81 mmol/g), swollen in DMF, followed by 22 mg (0.178 mmol, 0.2 eq) 
of DMAP. After shaking for 4 h, the resin was filtered and washed with DMF (5 x 5 
mL) followed by DCM (3 x 5 mL). The loading was calculated to be 0.525 mmol/g, 
corresponding to a 59 % yield. The remaining free hydroxyl functionalities were 
capped by treating the resin with a mixture of acetic anhydride/pyridine/DCM (112/2) 
and shaking for 2 h. The resin was washed as described above, dried over a vacuum 
pump and stored at 0 oC. 
Supported Fmoc-L-prolinyl-L-phenylalaninate 7 
In a 20-mL syringe tube equipped with a stopcock and a Teflon tilter, resin 6 (2.34 g, 
0.77 mmol) was deprotected according to the general procedure for Fmoc removal. The 
amino ester resin was then swollen in the minimum volume of DMF (l0 mL), treated 
with EDC-HCI (741.6 mg, 3.85 mmol), HOBt (478.1 mg, 3.5 mmol), Fmoc-Pro-OH 
(1.24 g, 3.5 mmol) and DIEA (0.672 mL, 3.85 mmol), shaken for 6 h, filtered and 
washed as described above, after which the resin exhibited a negative Kaiser test. 
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Method A: 81.8 % purity, method B: 91.2 % purity. 
Supported Fmoc- L-leucinyl-L-prolinyl-L-phenylalaninate 8 
As described above for resin 6, resin 7 was placed in a syringe tube, the Fmoc group 
was removed and the dipeptide resin was treated with HOBt (478 mg, 3.5 mmol), 
HBTU (1.32 g, 3.5 mmol), Fmoc-Leu-OH (1.24 g, 3.5 mmol) and DIEA (1.34 mL, 7 
mmol) in 10 mL of DMF, shaken for 4 h, filtered and washed, after which the resin 
exhibited a negative Kaiser test. Method A: 79.6 % purity, method B: 100% purity. 
Supported Fmoc-L-glutaminyl-L-prolinyl-L-leucinyl-L-phenylalaninate 9 
As described above, in the same reactor tube used in the last step, resin 8 was first 
treated under the general Fmoc deprotection protocol and then swollen in DMF and 
coupled to Fmoc-Gln-OH (1.55 g, 4.2 mmol) using HATU (1.59 g, 4.2 mmol) and 
DIEA (1.75 mL, 8.4 mmol) with shaking for 6 h. After filtration and washing as 
described above, the resin exhibited a negative Kaiser test. Method A: 80.2 % purity, 
method B: 94.5 % purity. 
Supported Fmoc-ê-aminocaproyl-L-glutaminyl-L-prolinyl-L-leucinyl-L-phenylalaninate 10 
As described above, in the same reactor tube used in the last step, resin 9 was first 
treated under the general Fmoc deprotection protocol and then swollen in DMF (13 mL) 
and coupled to N-Fmoc-ro-amino caproic acid (1.237g, 3.5 mmol) using EDe-HCl 
(741.6 mg, 3.85 mmol), HOBt (478.1 mg, 3.5 mmol), and DIEA (0.672 mL, 3.85 mmol) 
with shaking for 6 h. After filtration and washing as described above, the resin 
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exhibited a negative Kaiser test. Method A: 66.1 % purity, method B: 85.0 % purity. 
Tokyo Green Peptide 11a. Resin 10 (500 mg, 0.16 mmol) was placed in a 12-mL 
syringe tube, swollen in 6 mL of DMF for 20 min, filtered, treated with 4 mL of a 
solution of 20% piperidine in DMF, and shaken for 30 min. The resin was filtered and 
washed with DMF (5 x 5 mL) followed by DCM (3 x 5 mL), when a positive Kaiser 
test was observed. The resin was swollen with DMF (10 mL) and coupled to Tokyo 
Green (4,56 mg, 0.16 mmol) using EDC-HCl (46.3 mg, 1.5 mmol), HOBt (26.22 mg, 
1.2 mmol), DMF (3.2 mL) and DIEA (43 !lI, 0.24 mmol) with shaking for 6 h. The 
resin was filtered and washed with DMF (5 x 5 mL) followed by DCM (3 x 5 mL), 
when a negative Kaiser test was observed. The resin was treated with al: 1 solution of 
TF A/DCM (5 mL), shaken for 2 h, filtered and washed three times each with TF A (3 
mL) and DCM (5 mL). The collected filtrate and washings were combined and placed 
on a rotary evaporator to remove the volatiles. The residue was dissolved in water, and 
freeze-dried. The crude material was purified by preparative HPLC on Prevail 
C18 (250 x 22 mm, 5 micron) column using 30-80 % acetonitrile in water as eluant, a 
flow rate of 15 mL/min and the detector set at 214 nm. The collected fractions were 
freeze-dried to give the desired fluorescent peptide 11a (40 mg) as an orange powder. 
HRMS m/z (M+H+): calcd 945.4393. found 945.4394. 
Fluoresceine peptide llb. Resin 10 (300 mg, 0.105 mmol) was placed in a 12 mL syringe 
tube, swollen in 5 mL of DMF for 20 min, filtered, treated with 3 mL of a solution of 20% 
piperidine in DMF, and shaken for 30 min. The resin was filtered and washed with DMF (5 
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x 5 mL) followed by DCM (3 x 5 mL), when a positive Kaiser test was observed. The resin 
was swollen with DMF (10 mL) and coupled to fluorescein isocyanate (163.6 mg, 0.42 
mmol) using DIEA (74 ~L, 0.42 mmol) with shaking for 6 h. The resin was filtered and 
washed with DMF (5 x 5 mL) followed by DCM (3 x 5 mL), when a negative Kaiser test 
was observed. The resin was treated with a 1:1 solution ofTFAlDCM (5 mL), shaken for 2 
h, filtered and washed three times each with TF A (3 mL) and DCM (5 mL). The collected 
filtrate and washings were combined and placed on a rotary evaporator to remove the 
volatiles. The residue was dissolved in water, and freeze-dried. The cru de material was 
purified by preparative HPLC on Prevail C18 (250 x 22 mm, 5 ~L) column using 20-80 % 
acetonitrile in water as eluant, a flow rate of 15 mL/min and the detector set at 214 nm. The 
collected fractions were freeze-dried to give fluorescent peptide llb (56 mg) as a red 
powder. HRMS mlz (M+H+): calcd 1006.4015. Found 1006.4027. 
Dansyl Peptide He. Resin 10 (520 mg, 0.182 mmol) was placed in a 12 mL syringe tube, 
swollen in 5 mL of DMF for 20 min, filtered, treated with 3 mL of a solution of 20% 
piperidine in DMF, and shaken for 30 min. The resin was filtered and washed with DMF (5 
x 5 mL) followed by DCM (3 x 5 mL), when a positive Kaiser test was observed. The resin 
was swollen with DMF (10 mL) and coupled to dansyl chloride (149 mg, 0.55 mmol) using 
DIEA (96~L, 0.55 mmol) with shaking for 4 h. The resin was filtered and washed with 
DMF (5 x 5 mL) followed by DCM (3 x 5 mL), when a negative Kaiser test was observed. 
The resin was treated with al: 1 solution of TF AlDCM (5 mL), shaken for 2 h, filtered and 
washed three times each with TF A (3 mL) and DCM (5 mL). The collected filtrate and 
washings were combined and placed on a rotary evaporator to rem ove the volatiles. The 
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residue was dissolved in water, and freeze-dried. The crude material was purified by 
preparative HPLC on Prevail C18 (250 x 22 mm, 5Jl) column using 40-80 % acetonitrile in 
water as eluant, a flow rate of 15 mL/min and the detector set at 214 nm. The collected 
fractions were freeze-dried to give the fluorescent peptide He (60 mg) as a green powder. 
HRMS m1z (M+H+): ca1cd 850.4168. Found 850.4173. 
Synthesis of (5-amino-pentyl)-carbamic acid tert-butyl ester (14a). 
Di-tert-butyl dicarbonate (2.13 g, 9.8 mmol) in 40 mL of9:1 dioxane/water was added to a 
solution of 1,5-diaminopentane (Ba, 2 g, 19.6 mmol) in 60 mL of9:1 dioxane/water over a 
period of 4 h. The solution was stirred at room temperature ovemight and concentrated. The 
residue was taken up in 40 mL ofwater. The white precipitate corresponding to the N,N-di-
Boc-l,5-diaminopentane was removed by filtration through a fritted glass funnel, and the 
filtrate was extracted with CH2Ch (4 x 30 mL). The combined organic extracts were 
concentrated. The product was purified by silica gel chromatography (90: 10 
CH2Ch/methanol). Evaporation of the coUected fractions provided N-(Boc)-1,5-
diaminopentane 14a (1.4 g, 6.95 mmol, 71%) as a dense liquid; IH NMR (CDCi), 300 
MHz) 8 4.63 (s, lH), 3.1 (dd, 2H, J = 6.0, J = 12.4), 2.68 (t, 2H, J = 6.7), l.75 (s, 3H), 
1.49-l.52 (br, 3H), l.42 (S, 9H), l.27-l.36 (br, 2H). l3C NMR (CDCi), 300 MHz) 8 156.85, 
79.86,42.77,41.29,33.99,30.72,29.23,24.86. HRMS m/z (M+H+): ca1cd for CIOH22N204 
203.1754. found 203.176l. 
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Synthesis of (5-[5-(2-oxo-hexahydro-thieno[J,4-d]imidazol-4-yl}-pentanoylamino]-pentyl)-
earbamie acid tert-butyl ester (lSa). 
A solution of D-biotin (153 mg, 0.625 mmol) in 3 mL of DMF was treated with amine 
(14a) (151 mg, 0.751 mmol), HOBt (103 mg, 0.751 mmol), EDC-HCI (181 mg, 0.938 
mmol) and DIEA (1.2 mL, 0.938 mmol) and stirred at room temperature for 4 h, when TLC 
showed disappearance of the starting amine (Rf = 0, solvent: 5% MeOH/95% CHCh) and 
appearance of a new product (Rf = 0.1, solvent: 5% MeOH/95% CHCh). The volatiles were 
removed by evaporation, and the residue was dissolved in 110 mL of EtOAc and washed 
with brine (3 x 20 mL) then saturated sodium bicarbonate (3 x 20 mL), and dried over 
MgS04. The organic layer was evaporated to give amide lSa (167.1 mg, 61 %) as a white 
powder:; tH NMR (400 MHz, MeOD) ù 4.51 (br, IH), 4.32 (br, IH), 3.33 (br, lH), 3.2 (m, 
3H), 3.04 (m, 2H), 2.95 (dd, IH, J 5, J 12.7), 2.73 (d, IH, J=12.7), 2.21 (t, 2H, J=7.4), 
1.75 (m, IH), 1.36 (m, 2H), 1.64 (m, 3H), 1.51 (m, 5H), 1.45 (s, 9H), 13C NMR (400 MHz, 
MeOD) ù 174.2, 164.3, 156.7, 78.0, 61.6, 59.9, 55.2, 39.5, 39.3, 38.5, 35.1, 28.8, 28.3, 
28.0, 27.0, 25.1, 23.4. HRMS m1z (M+H+): calcd 429.2535 for for C2oH36N404S. found 
429.2533. 
Synthesis of 5-(2-oxo-hexahydro-thieno{3,4-d]imidazol-4-yl)-pentanoie acid (4-amino-
butyl)-amide hydrochloride salt (16a) 
To a solution of carbamate lSa (100 mg, 0.23 mmol) in MeOH (3 mL), aqueous HCI (lM, 
0.4 mL) was added and the mixture was stirred for 2h. The volatiles were removed under 
vacuum to afford amine hydrochloride 16a as a yellow gel in quantitative yield (83.9 mg): 
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IH NMR (400 MHz, CD30D) cS 4.50 (br, IH), 4.32 (br, IH), 3.32 (br, IH), 3.2 (m, 3H), 
2.93 (m, 3H), 2.68 (d, IH, J= 8.9), 2.21 (t, 2H, J= 9.7),1.67 (m, 4H), 1.58 (m, 3H), 1,44 
(m,3H). HRMS mlz (M+H+): calcd 329.2006 for ClsH28N402S. found 329.2002. 
{2-[2-(2-amino-ethoxy)-ethoxyj-ethyl}-carbamic acid tert-butyl ester 14b. 
To a solution of Et3N (9,41 mL, 67.5 mmol) in Me OH (200 mL), tris(ethylene glycol)-1,8-
diamine (5 g, 33.7 mmol) and di-tert-butyl dicarbonate (7.36g, 33.7 rnmol) were added. 
The reaction was stirred for 1 h. The volatiles were evaporated and the residue was 
dissolved in 200 mL ofCH2Ch, washed with a saturated solution ofNa2C03 (2 x 150 mL), 
dried over Na2S04 and filtered. The volatiles were evaporated and the residue was purified 
by silica gel chromatography (CH2Ch/MeOHINH40H 55/4/0.2) to afford carbamate 14b 
(2.68 g, 32%) as an oil; l H NMR (d6-DMSO, 300 MHz) cS 1.37 (s, 9H, 3CH3), 1.81 (br. s, 
2H, NH2), 2.64 (t, J = 5.75, 2H, CH2NH2), 3.06 (m, 2H, CH2NH-Boc), 3.35 (t, J = 5.79, 
2H, CH2CH2NH2), 3.38 (t, J = 6.3, 2H, CH2CH2NH-Boc), 3,49 (s, 4H, O(CH2)2), 6.81 (br. 
t, IH, NH-Boc). l3C NMR (d6-DMSO, 75 MHz) cS 29,47, 40.97, 42.63, 70,49, 70.81, 70.85, 
74.34, 78.79, 156.87. HRMS mlz (M+H+): calcd for C9H24N204 203.1754. found 203.1761. 
[2-(2-{2-[5-(2-oxo-hexahydro-thieno[3,4-djimidazol-4-yl)-pentanoylaminoj-ethoxy}-
ethoxy)-ethyl}-carbamic acid tert-butyl ester 15b. 
To a solution of amine 14b (500 mg, 2.01 mmol) and DIEA (770 mL, 4,42 mmol) in 
anhydrous DMF (50 mL), D-biotin (540 mg, 2.21 mmol) and TBTU (905 mg, 2.82 mmol) 
were added and the reaction mixture was stirred at room temperature for 18 h. The volatiles 
were evaporated. The residue was dissolved in EtOAc (100 mL), washed with a saturated 
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solution of Na2C03 (2 x 100 mL), dried over Na2S04, filtered and evaporated. The residue 
was purified by silica gel chromatography (CH2Ch/MeOHINH3 55/4/0.4) to afford amide 
15b (954 mg, 1.15 mmol, 57% yield) as a white solid: mp: 102 oC; IH NMR (d6-DMSO, 
300 MHz) Ù 1.15-1.66 (m, 15H, 3CH2, 3CH3), 2.06 (t, J =7.31, 2H, CH2C=O), 2.55-2.81 
(m, 2H, CH2S), 3.02-3.12 (m, 3H, CH2NH-Boc, CHS), 3.17 (m, 2H, CH2NHC=O), 3.34-
3.40 (2t, 4H, 2CH2CH2N), 3.48 (s, 4H, O-(CH2h), 4.10-4.14 (m, IH, CHN), 4.28-4.32 (m, 
IH, CHN), 6.38 (s, IH, NH), 6.45 (s, IH, NH), 6.78 (br. t, IH, NH-Boc), 7.85 (br. t, IH, 
NHC=O). 13C NMR (d6-DMSO, 75 MHz) Ù 26.57, 29.33, 29.52, 36.38, 39.73, 40.96, 
41.16,56.73,60.50,62.34, 70.47, 70.75, 70.82, 78.89, 156.88, 164.04, 173.43. HRMS mlz 
(M+Na+): calcd for C21H38N406S 271.1628. found 271.1624. 
5-(2-0xo-hexahydro-thieno{3,4-d]imidazol-4-yl)-pentanoic acid (2-{2-(2-amino-ethoxy)-
ethoxy]-ethyl}-amide hydrochloride salt (l6b). 
Employing the same procedure described above for the synthesis of amine hydrochloride 
16a, carbamate 15b (60 mg, 0.14 mmol) was quantitatively converted to amine 
hydrochloride 16b which was isolated as an amorfous solid: mp: 111°C; IH NMR 
(CD30D, 300 MHz) Ù 1.41-1.82 (m, 6H, 3CH2), 2.25 (t, J=2.25, 2H, CH2C=O), 2.72-3.00 
(m, 2H, CH2S), 3.14 (br. t, 2H, CH2NHC=O), 3.22-3.28 (m, IH, CHS), 3.39 (t, J= 5.6, 2H, 
CH2), 3.58 (t, J = 5.6, 2H, CH2), 3.68 (s, 4H, O(CH2)Û, 3.73 (t, J = 5.1, 2H, CH2), 4.35-
4.40 (m, lH, CH), 4.55-4.59 (m, IH, CH). 13C NMR (CD30D, 75 MHz) Ù 26.89, 29.50, 
29.75, 36.69, 40.25, 40.71, 40.96, 56.99, 62.09, 63.76, 67.92, 70.64, 71.30, 71.39. HRMS 
mlz (M+Na+): calcd for Cl6H30N404S 497.2404. Found 497.2401. 
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{2-(2-Amino-ethyldisulfanyl)-ethyl}-carbamic acid tert-butyl ester (l4e). 
This compound was prepared according to the same procedure described to make 
carbamate 14b above using Et3N (9.41 mL, 67.5 mmol), MeOH (200 mL), cysteamine 
disulfide (5.12 g, 33.72 mmol), and di-tert-butyl dicarbonate (7.36, 33.72 mmol). 
Purification by silica gel chromatography (CH2Ch/MeOHI1\1H3 55/4/0.2) gave carbamate 
14e (3.03 g, 12.00 mmol, 29% yield) as yellow solid: mp: 92 oC; lH NMR (d6-DMSO, 300 
MHz) 8 1.37 (s, 9H, t-Bu), 2.68-2.80 (m, 6H, NCH2CH2S, NCH2CH2S, NH2CH2CH2S), 
3.19 (m, 2H, SCH2CH2NH-Boc), 7.00 (br t, IH, NH). l3C NMR (d6-DMSO, 300 MHz) 8: 
29.51, 38.94, 40.73, 42.21, 43.36, 79.04, 156.79. HRMS m/z (M+H+): ca1cd for 
C9H20N202S2 253.1039. Found 253.1040. 
(2 -{2 -[5 -(2 -Oxo-hexahydro-thie no [3, 4 -dJ imidazol-4-yl)-pe ntanoylamino J -ethyldisulfanyl}-
ethyl)-carbamic acid tert-butyl ester (lSe). 
This compound was prepared from amine 14e (1.41 g, 5.59 mmol), DIEA (2.14 mL, 12.3 
mmol), D-biotin (1.4 g, 5.8 mmol) and TBTU (2.5 g, 7.84 mmol) using the same protocol 
as described for amide 15b. Purification by silica gel chromatography (CH2Ch/MeOHINH3 
55/4/0.4) afforded amide 15e (1.44 g, 3.02 mmol, 54% yield) as a white solid: mp: 112 oC; 
lH NMR (d6-DMSO, 300 MHz) 8 1.23-1.66 (m, 15H, 3CH2, 3CH3), 2.06 (t, J = 7.33, 2H, 
CH2C=O), 2.69-2.85 (m, 6H, 3CH2S), 3.06-3.12 (m, IH, CH-S), 3.19 (m, CH2, CH2NH-
Boe), 3.31 (m, 2H, CH2NHC=O), 4.10-4.14 (m, IH, CH), 4.28-4.32 (m, IH, CH), 6.37 (br. 
s, IH, NH), 6.43 (br. s, IH, NH), 6.99 (br. t, IH, NH-Boc), 7.98 (br. t, IH, NH). l3C NMR 
(d6-DMSO, 75 MHz) 8 26.53, 29.33, 29.52, 36.44, 38.65, 38.81, 39.12, 40.68, 56.72, 60.48, 
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62.32, 79.10, 156.81, 164.00, 173.47. HRMS m/z (M+H+): calcd for Cl9H34N404S3 
479.1815. found 479.1819. 
5-(2 -Oxo-hexahydro-thie no [3, 4-dJ imidazol-4-yl)-pentanoic 
ethyldisulfanyl)-ethylJ-amide hydrochloride salt (16e). 
acid [2-(2-amino-
Employing the same procedure described above for the synthesis of amine hydrochloride 
16a, carbamate ISe (300 mg, 0.63 mmol) was quantitatively converted to amine 
hydrochloride 16e which was isolated as a solid: mp: 119 oC; IH NMR (d6-DMSO, 300 
MHz) 8 1.22-1.65 (m, 6H, 3CH2), 2.06 (t, 2H, CH2C=O), 2.53-2.83 (m, 4H, CH2S, CH2S), 
2.94 (t, J= 6.51, 2H, NH2CH2CH2S), 3.01-3.10 (m, 3H, CHS, CH2NH2), 3.27-3.34 (m, 2H, 
CH2NHC=O), 8.11 (t, 1 H, NHC=O), 8.17 (br. s, 3H -NH3). J3C NMR (d6-DMSO, 75 MHz) 
826.54,29.33,29.48,35.17,35.29,36.42,38.50,39.15, 41.15, 56.73, 60.52, 62.36,164.05, 
173.61. HRMS m/z (M+H+): calcd for Cl4H26N402S3 379.1291. found 379.1276. 
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3.1 Introduction 
Fluorescence resonance energy transfer (FRET) is a use fuI contemporary technique for 
studying proximity effects of macromolecules. The FRET phenomenon involves the non-
radiant energy transfer from an excited fluorophore donor to an acceptor molecule through 
a dipole-dipole interaction. 69 The acceptor may in turn release the energy at a different 
wavelength. The energy transfer efficiency is dependant upon many factors, such as the 
spectral overlap, the relative orientations and the distance between the donor and acceptor 
pair. 70, 71 FRET is detected at a lOto 100 A distance between the donor and acceptor pair 
contingent on orientation, as expressed by the Forster value Ro (equation 3.1). 12 
Ro= 9.78 x 103 (k2 n-4Qo J(À-) )1/6 (A) (equation3.l). 
where k2 describes the donor/acceptor transition dipole orientation and can range in value 
from 0 (perpendicular) to 4 (collinear/parallel). The refractive index "n" is ascribed a value 
of lA for biomolecules in aqueous solution; Qo is the quantum yield of the donor in the 
absence of the acceptor; J(À-) is the overlap integral which represents the degree of spectral 
overlap between the don or emission and the acceptor absorption ( Figure 3.1). The values 
for J(À-) and Ro increase with higher acceptor extinction coefficients and greater overlap 
between the donor emission spectrum and the acceptor absorption spectrum. 
FRET efficiency is determined by either the steady-state (Equation 3.2) or the time resolved 
measurement (Equation 3.3). In the following equations, F is the relative donor 
fluorescence intensity in the absence (Fo) and presence (FoA) of the acceptor, and t is the 
fluorescent lifetime of the don or in the absence (to) and presence (tOA) of the acceptor. 
(Equation 3.2). 
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(Equation 3.3). 
Figure 3.1: FRET dependence on the overlap integrals. 
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FRET has been widely used in enzymatic activity detection assays. 70,71 for example, the 
activity of proteases, 73 and phosphodiesterases 74 have been monitored by the 
disappearance of FRET signal on enzyme-catalyzed c1eavage of the fluorophore pair linked 
the substrate. 
TGase catalyzes isopeptide bond formation. The donor and acceptor substrates were thus 
labeled each with one member of a FRET pair of fluorophores that could engage in energy 
transfer when brought in close proximity. The FRET pair of 7-hydroxycournarin (which is 
excited at 400 nrn and emits at 460 nrn) and Tokyo Green or fluorescien thiourea (which 
are typically excited at 490 nrn and emits at 515 nm) has previously been employed as 
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indicator of DNA structure in solution 75 as weil as in protein labeling studies. 76 Donor and 
acceptor substrates were thus labeled with thesè two fluorophores. Upon TGase-induced 
isopeptide bond formation, a fluorescence decrease at 460 nm was observed (emission of 
the 7 -hydroxycoumarin) as weil as fluorescence increase measured at 515 nm (emission of 
Tokyo Green and Fluorescein thiouea). The fluorescence decrease of 7-hydroxycoumarin 
(Àexc 405 nm, Àem 460 nm) was effectively monitored using purified enzyme with high 
, 
sensitivity (4 mU enzyme concentration). This method was also effective in a more 
complex biological system of Iysates of E. coli that express TGase enzyme. Furthermore, 
this method was applied to 96-well microtiter plate format, for high-through put screening. 
3.2 General 
Enzyme preparation 
Recombinant guinea pig liver TGase was over-expressed and purified from E. coli 
following the published procedure. 63 The purified TGase solution used in all assays was 
shown to have a specifie activity of 14 U/mg (2.5 mg/mL) in 25 mM oftris-acetate (pH 7) 
buffer using the hydroxamate activity assay, 64 in which Cbz-Gln-Gly and hydroxylamine 
were used as acyl-donor and acyl-acceptor substrates, respectively. 
J. 
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Figure 3.2: Scheme of FRET for Tokyo Green/7-hydroxycoumarin carboxylic acid pairs 
Excitation 405 nm Emission 465 nm 
o 
TGase 
Excitation 405 nm Emission 518 nm 
o 
FRET 
Preparation ofcrude bacteriallysate 
L ysate was prepared using the same protocol as described in chapter 2. 
Material 
The buffer solution in ail assays was tris.HCl 100 mM, EDTA 0.6 mM, 10 mM CaCh, (pH 
8). The washing buffer solution was a mixture of 100 mM phosphate, 100 mM NaCl, and 
0.1 % SDS (pH 8). Water was purified using a Millipore BioCell water purification system. 
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3.3 Synthesis of the acyl acceptor substrate 
7-Hydroxy-3-coumarin carboxylic acid was prepared as reported in the literature, 72 and 
was then coupled to mono-protected N-Boc-diamine 14a. Boe deprotection of 19 was 
performed using trifluoro acetic acid in DCM. The TF A salt was exchanged with 1 M HCI 
solution to provide the hydrochloride salt for enzymatic studies (Scheme 3.1). 
Scheme 3.1: Synthesis of the acyl acceptor substrate 
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3.4 Synthesis of the acyl donor substrate 
Peptides 11a and 11b, as previously described in Chapter 2, were chosen as acyl donor 
candidates due to their high affinities to TGase. Furthermore, they offered better spectral 
overlap with 7-hydroxy-3-coumarin for FRET. 76,77 
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3.5 FRET assay using purified tissue TGase 
3.5.1 Methods 
AIl assays were performed in triplicate. Acyl donor substrate lIa or b (10 J.tL, 0.6 mM) and 
acyl acceptor substrate 20 (10 J.tL, 0.6 mM) were combined in 80 J.tL ofbuffer solution, 12 
J.tL of DMF, and 78 J.tL of water at a final volume of 190 J.tL. The reaction was initiated by 
addition of 25 J.tg (10 J.tL) of purified TGase or an equivalent volume of 25 mM tris-acetate 
buffer was added for the blank. Fluorescent spectra were measured after 1, 2, 5, 10, 20, 40, 
80 and 140 min of incubation. At each time, an aliquot of the parent solution (7 J.tl) was 
diluted with a mixture of 200 J.tL MeOH, 200 J.tL buffer, and 200 J.tL water. The decrease in 
fluorescent signal corresponding to enzyme activity was measured relative to the blank 
solution using a Perkin Elmer Bio Assay Reader (HTS 7000). Excitation and emission 
wavelengths were respectîvely Àexc = 405 nm and Àem = 465 nm, and the gain was set at 52 
unÏts. 
3.5.2 Results and discussions 
The change of fluorescence was measured at different times after incubation of 11a or 11b 
with 20 in the presence of TGase. Excitation at 405 nm caused a continuous emission 
decrease at 460 nm corresponding to the decrease of the fluorescence of 7-hydroxy-
coumarin carboxylîc acid. Simultaneously, a continuous increase of fluorescence at 518 nm 
corresponded to the fluorescence emission of Tokyo Green for a typical fluorescence 
resonance energy transfer (Figure 3.4). 
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Figure 3.4: FRET assay sensitivity with acyl donor lla-b and acyl acceptor 20 usmg 
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In the spectra, the fluorescence decrease at 465 nm was greater than the increase at 515 nm 
for both the Tokyo Green and fluorescein labeled peptides. In light of this fact, changes in 
fluorescence were measured at 465 nm. The relative decrease of fluorescence due to non 
specific quenching was presumed to be negligeable because the same sample of lysate was 
used for aIl experiments. 
The decrease in fluorescence at 465 nm, and increase of fluorescence signal at 515 nm were 
observed to cross at 510 nm, when the spectra were measured at different incubation times. 
This specific wavelength is caIled the isosbestic point and is characteristic in spectroscopy 
of species having the same extinction coefficients (at the same concentration). It is a 
consequence of having a two-state system; the transamidation reaction is consistent with 
this two-state system (substrates vs product, with no appreciable intermediate state). 
The decrease of fluorescence at 465 nm was greater in the case of the 7 -hydroxycoumarinl 
Tokyo Green pair (a decrease of 510 units after 80 min) relative to that of the 7-
hyâroxycoumarinl fluorescein thiourea pair (a decrease of 300 units after 80 min). The 
fluorescence increase was similarly more pronounced for the 7-hydroxycoumarinl Tokyo 
Green pair relative to the 7-hydroxycoumarinl fluorescein thiourea pair. The conditions 
used for the measurements may influence the sensitivity of the assay. For example, 
fluorescence emission of fluorescein thiourea possessing a carboxylic acid at the l' position 
of the aromatic system is greatly influenced by pH because of lactam formation. Tokyo 
Green, which has a greater quantum yield and no carboxyl functionality at the 1 position, 
gave a stable signal over a wide range ofpH. 62 
,f 
1 
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In order to confirm that this assay was in fact measuring fluorescence change resulting from 
enzymatic formation of the final product formation, and not due to the formation of a 
precipitate that could not be detected by the naked eye, control experiments were 
performed. 
• Spectrometry: 
LCMS-MS analysis (0-40% acetonitrile, H20, 0.1% formic acid, 0.5 mL! min, À,= 214 nm, 
Agilent LCMSD, column: C6 Phenyl, 3H, 50 x 4.6 Gemini) was perfonned on sample 
aliquots from enzymatic and non enzymatic reactions using acyl donor Ha (Figure 3.5) and 
acyl acceptor 20. From the non enzymatic sample spectrum, a single peak with a molecular 
weight of 945.4 g/mol (7.15 min retention time) corresponding to the acceptor substrate 
Ha, was observed. From the enzymatic sample, a peak with a molecular weight of 1218.1 
g/mol (7.26 min retention time) corresponding to the exact mass of the amide product 21 
was observed (Figure 3.6) without trace ofl1a. 
Figure 3.5: Product formed upon transamidation by TGase 
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Figure 3.6: LCMS spectrum of the enzymatic and non enzymatic reactions 
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3.5.3 Limits of detection 
To further demonstrate the practical value of the FRET assay in plate format, a continuous 
experiment as described in the methods section was perfonned under enzymatic (35 U/mL) 
and nonenzymatic conditions (Figure 3.7) using purified TGase. As clearly shown, the 
time-dependent decrease in fluorescence was pronounced. 
Figure 3.7: Application of the FRET assay on plates. 
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ln order to detennine that continuous fluorescence decrease was solely due to FRET, the 
donor and the acceptor substrates were separately incubated with and without enzyme 
(Figure 3.8). The spectra exhibited no decrease of fluorescence, in the absence of the FRET 
paIr. 
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Figure 3.8: Control test for the FRET assay on plate 
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The limits of detection of TGase by the assay with respect to concentration was determined 
using various concentrations of purified enzyme with acyl donor 11a and acyl acceptor 20, 
as described under Methods. For correlation of the signal with enzymatic activity, the 
decrease of fluorescence at 465 nm was followed as shown for a typical kinetic experiment 
with different amounts of purified enzyme (Figure 3.9). The FRET effect upon ligation by 
TGase could be followed kinetically and continuously using this assay. The minimum 
amount of enzyme reliably detected at different enzyme concentrations corresponded to 
4mU (Figure3.9). 
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Figure 3.9: Limit of detection of the FRET assay 
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Ali assays were performed in triplicate_ Acyl donor substrates 11a and 11 b (10 ilL, 0.6 
mM) were respectively incubated with the acyl acceptor substrate 20 (10 ilL, 0_6 mM) in 80 
ilL of buffer solution and 12 ilL DMF, giving a final volume of 200 ilL The reaction was 
initiated by addition of lysate (2.5 ilL, 0.90 U/mL) or an equivalent volume of the lysate of 
E. coli cells void of the expression plasmid, as the blank. Enzyme activity was measured 
by monitoring the decrease of the signal of fluorescence relative to the blank using a Perkin 
Elmer Bio Assay Reader (HTS 7000) using Àexc = 405 nm and Àem = 465 nm for substrate 
11a and 11b with the gain set at 52 units _ 
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3.6.2 Result and discussion 
Detection of enzymatic activity in complex biological samples is of practical value for 
high-throughput screening. The coupling of acyl donor Ha and acyl acceptor 20 was thus 
studied using crude lysate of E. coli expressing recombinant TGase. Expression of TGase 
was performed in small volume cultures in 48 weIl plates as described under Methods 
Section. The lysate of E. coli void of the expression plasmid was used as a negative control. 
From each culture, cellular lysate of 200 ~L were obtained, from each lysate an aliquot of 
2.5 ~L (- 2.5 mU) was removed and incubated with substrate. Enzymatic substrate ligation 
in lysate samples was monitored using a plate reader, by following the decrease in 
fluorescence at 465 nm (Figure 3.10) over a period of 130 min. 
When analyzing TGase activity in complex biological samples, assays that measure only 
the first step of the transamidation may give artificially higher activities due to competing 
acyl donor hydrolysis. In contrast to such assays which report the extent of acylation of the 
enzyme, detection of fluorescence in the present assay is a consequence of formation of an 
amide 21 as earlier demonstrated (Figure 3.6). 
As shown in Figure 3.10, the experiment was executed in triplicate. In the first three wells 
were incubated the lysates of cells that did not express the TGase: the fluorescence 
remained constant. In the last three wells, the lysates with TGase showed a great decrease 
in fluorescence. 
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Figure 3.10: Continuous FRET assay using crude bacteriallysate 
The assay was shawn ta be reproducible and sensitive for the detection of the TGase 
activity (Figure 3.10). 
The spectral change caused by the FRET effect was visible ta the naked eye (Figure 3.11). 
The yellow color that was observed in the absence of TGase changed ta orange in presence 
ofTGase. 
Figure 3.11 Sensitivity of the FRET assay: (AI-3: 10 ilL of 0.6 mM of acyl donor 11a, 10 
ilL of 0.6 mM of acyl donor 20, 80 ilL Buffer, 100 /-LL H20; A4-6: 10 ilL of 0.6 mM of 
acyl donor 11a, 10 ilL of 0.6 mM of acyl donor 20, 80 ilL Buffer, 97.5 ilL H20, 2.5 III 
lysate) . 
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3.7 Conclusion 
A FRET assay has been developed for monitoring TGase activity. The reproducibility, 
sensitivity in a series of control experiments and efficiency of this continuous assay were 
demonstrated. Moreover, the assay proved sensitive for detecting TGase activity in lysate. 
This method offers potential for high-throughput screening of TGase mutants for new 
activities. 
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3.8 Experimental section 
Synthesis of the FRET donor substrate 
Synthesis of 7 -hydroxy-coumarin-3-carboxylic acid (18) 
A mixture of 2,4-dihydroxyl benzaldehyde (2g, 20 mmol), Meldrum's acid (2.89g, 20 
mmol), piperidinium acetate (58 mg, 0.4 mmol) and ethanol (10 mL) was stirred at room 
temperature for 20 min, and then heated at reflux for 2 h. The reaction mixture was allowed 
to cool down to room temperature, then chilled in an ice bath for lh. The crystallized 
product was filtered, washed three times with ethanol, and dried in vacuo yielding 18 (3.4 
g, 83%) as a brown powder; IH NMR (DMSO-d6, 400 MHz) cS 8.66 (s, 1H), 7.73 (d, 1H, J= 
8.5), 6.84 (d, 1H, J= 8.4), 6.73 (s, 1H). 13C NMR (DMSO-d6, 100 MHz) 
cS 164.3, 164.1, 157.7, 157.1, 149.3, 132.1, 114.1, 112.7, 110.7, 101.9. 
(5-Amino-pentyl)-carbamic acid tert-butyl ester (14a). 
A solution of di-tert-butyl dicarbonate (2.13 g, 9.8 mmol) in 40 mL of 9: 1 dioxane/water 
was added over a period of 4 h to a solution of 1,5-diaminopentane (2 g, 19.6 mmol) in 60 
mL of 9: 1 dioxane/water. The solution was stirred at room temperature ovemight and 
concentrated under rotory evaporated. The residue was taken up in 40 mL of water. The 
white precipitate corresponding to the N,N -di-Boc-l ,5-diaminopentane was removed by 
filtration through a fritted glass funnel, and the filtrate was extracted with CH2Ch (4 x30 
mL). The combined organic extracts were concentrated. The product was purified by silica 
gel chromatography (90: 10 CH2Ch/methanol). Evaporation of the collected fractions 
provided N-(Boc)-1,5-diaminopentane 14a (1.4 g, 6.95 mmol, 71%) as a dense liquid: bp 
97 oC; IH NMR (CDCh, 300 MHz) cS 4.63 (s, 1H), 3.1 (dd, 2H, J = 6.0, J = 12.4), 2.68 (t, 
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2H, J = 6.7), 1.75 (s, 3H), 1.49-1.52 (br, 3H), 1.42 (S, 9H), 1.27-1.36 (br, 2H). BC NMR 
(CDCi), 300 MHz) Ô 156.85, 79.86, 42.77, 41.29, 33.99, 30.72, 29.23, 24.86. HRMS mlz 
(M+H+): calcd for CIOH22N204 203.17540. found 203.1761. 
Synthesis of {5-[(7-hydroxy-2-oxo-2H-chromene-3-carbonyl)-aminoj-pentyl}-carbamic 
acid tert-butyl ester (19). 
A solution of acid 18 (30 mg, 0.15 mmol) in 3 mL of DMF was treated with amine 14a (31 
mg, 0.15 mmol), HOAt (21 mg, 0.15 mmol), EDC-HCl (29 mg, 0.15 mmol) and DIEA 
(0.027 mL, 0.15 mmol) and stirred at room temperature for 4 h, when TLC showed the 
disappearance of the starting amine (Rf = 0, solvent: 5% MeOH/95% AcOEt) and 
appearance of a new product (Rf = 0.2, solvent: 5% MeOH/95% AcOEt). The volatiles 
were removed by evaporation. The residue was treated with 5 mL of MeOH, when a white 
precipitate was formed. The precipitate was recovered by filtration onto a fritted funnel, 
washed with 3 x 2 mL of MeOH, and dried under vacuum ovemight yielding amide 19 
(50.1 mg, 87%) as white solid: mp 176.3 oC; IH NMR (DMSO d6, 400 MHz) Ô Ô Il.16 (s, 
IH), 8.77 (s, IH), 8.61 (t, IH, J= 5.6), 7.81 (d, IH, J= 8.6), 6.88 (dd, IH, J=8.6, J=2.2), 6.8 
(d, IH, J=2.1), 6.73 (br, IH), 3.18 (d, IH, J= 4.8), 2.91 (q, 2H, J= 12.8, J= 6.6),1.51 (m, 
2H), 1.36 (s, 9H), 1.28 (br, 3H). BC NMR (CDCI3, 100 MHz) 
Ô 164.9, 162.7, 162.4, 157.5, 156.9, 149.2, 133.2, 115.6, 115.1, 112.4, 103.1,78.6,30.5,30. 
1,29.5,25.0. HRMS mlz (M+Na+): ca1cd for C2oH26N206 413.1683. found 413.1695. 
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7-Hydroxy-2-oxo-2H-chromene-3-carboxylic acid (5-amino-pentyl}-amide (20). 
A solution of carbamate 19 (20 mg, 0.06 mmol) in a mixture ofTFAIDCM (lmLllmL) was 
stirred for 2 hours. The volatiles were removed under vacuum. A salt exchange was 
performed dissolving the residue twice in 2 mL of lM HCI and freeze-drying. Amine 
hydrochloride 20 was isolated as a yellow gel in quantitative yield (19.26 mg); Àex= 400 
nm, Àem= 448 nm. IH NMR (DMSO ~, 400 MHz) 0 11.16 (s, IH), 8.77 (br, lH), 8.61 (t, 
IH, J= 5.6), 7.81 (d, IH, J= 8.6), 6.88 (dd, IH, J=8.6, J=2.2), 6.8 (d, lH, J=2.1), 6.73 (br, 
tH), 3.18 (d, tH, J= 4.8), 2.91 (q, 2H, J= 12.8, 6.6), 1.51 (m, 2H). HRMS m/z (M+H+): 
calcd for C1sHI9N204 291.1341. found 291.1339. 
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Chapter4 
Concluding Statements and Future Work 
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4.1. Conclusion 
In order to develop a new library of mutant transglutaminases, which could be efficient 
biocatalysts for peptide coupling reactions, a series of cycles of enzyme mutations should 
be performed using different methods, such as PCR or gene shuffling. This necessitates the 
development of the appropriate enzyme expression methods for the mutants and the 
development of efficient methods for screening mutants for desired activity. 
Our project aim was to develop new methods for screening overexpressed TGase enzyme. 
For this goal two fluorometric methods have been developed for detecting activity of 
purified TGase as weIl as TGase in biological media. The first method was based on the 
great affinity of biotin to streptavidin or avidin protein. TGase catalyzes the reaction of a 
biotinylated amine as the y-glutamyl acceptor substrate and a short peptide - QLPF -
labeled with a fluorescent moiety as the y-glutamyl donor substrate. After the reaction, the 
conjugate was fixed on streptavidin-coated beads and excess unreacted substrate was 
washed away, allowing quantitation of the activity by fluorescence measurement. This 
method was used to detect the activity of as little as 8.25 IlU of purified enzyme, and was 
demonstrated to be applicable for detection of the activity from crude cellular lysates. This 
assay exhibits remarkable sensitivity, and may tolerate modifications of the fluorophore and 
biotin labeled substrates for potential screening to identify TGase mutants that recognize 
unnatural substrates. 
The second method was based on the fluorescence resonance energy transfer, (FRET) 
properties of a selected pair of fluorophores. 
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Donor and acceptor substrates labelled respectively with the chromophores Tokyo Green 
and 7-hydroxy coumarin, were used to detect TGase-catalyzed formation of an amide bond 
between these two substrates, by an observable FRET effect. On excitement of the system 
at 405 nm, fluorescence at 460 nm for the 7-hydroxy coumarin residue decreases with a 
concurrent increase in fluorescence at 515 nm for the emission of the Tokyo Green 
chromophore. On monitoring the decrease of fluorescence of the coumarin chromaphore 
O-exc 405 nm, Àem 460 nm), the activity of 4 mU purified enzyme could be measured . 
Moreover, this FRET -based assay has been used to examine TGase activity in the lysate of 
E. coli expressing the enzyme in a 96-well microtiter plate format, and may thus be suitable 
for high-throughput screening. 
4.2 Comparison of Methods 
The developed methods each contain different sensitivity, reproducibility and applications 
for high-throughput screening of enzyme activity . 
• :. Sensitivity 
The biotin-based method can detect a minimum enzyme activity of 8.25 IlU of purified 
enzyme. The FRET assay gives a sensitivity of 4 mM. Thus, the biotin method is much 
more sensitive than the FRET method . 
• :. Reproducibility 
In aIl cases, experiments were repeated in triplicates, and both methods indicated a very 
good reproducibility making theses methods applicable for high-throughput screening . 
• :. Application for high-throughput screening 
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An important criteria for method development in high-throughput screening is the number 
of assays conducted in the same day. The biotinylated method may be more sensitive than 
the FRET method; however, it is a discontinuous as say, making it difficult to calculate 
kinetics, and is also time consuming due to the multiple washing steps. The FRET assay is 
a continuous method and thus better suited for kinetic analyses, as well as for rapid 
screenmg. 
Numerically, a 96-well plate could be tested in the same day in the case of the bionylated 
assay. For the FRET as say, the 96-well plate could be tested in one hour. Moreover, this 
assay is val id for calculating kinetic parameters for both donor and acceptor substrates. 
Thus, the FRET method is a promising method for screening enzyme mutants for desired 
activities against a specific target. 
4.3 Future Work 
This work has been performed as a collaborative effort between members of the Lubell, 
Keillor and Pelletier groups in the Department of Chemistry at l'Universite de Montreal 
aimed at developing new mutant enzymes for the biocatalysis of peptide coupling reactions. 
Roberto Chica from the Keillor and Pelletier group has mutated transglutaminase by 
different biological techniques creating a promising library of enzyme mutants for the 
desired activity. 
Future work would involve demonstrating that those developed methods may tolerate 
modifications of the fluorophores and biotin labeled substrates for potential screening to 
identify TGase mutants that recognize unnatural substrates. The modification of the amino 
acid residue GIn with Asn within the acyl donor substrate (from QLPF to NLPF) will be the 
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next step to test the degree of tolerance of the library towards this important modification. 
In fact, since Asn has one less carbon in the side chain, which is a relatively minor 
modification, the aim is to select the mutants that could achieve the transpeptidation 
between the asparagine residue and the primary amine. Selected TGase mutants will also be 
tested with a variety of donor and acceptor substrates in order to determine their specificity. 
Assay optimization will go hand in hand with the development of TGase mutants with 
alternative transamidation specificity. 
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Peptide market finally ripening? 
13Jan·2005 - Peptide drugs look like they may finally fulfil their promise, after years of what has 
largely been disappointment, if figures released in a new market research report prove accurate. 
Although peptide drugs have been on the market for decades - insu lin being the most prominent example - it 
was not until 10 to 15 years ago that the pharmaceutical industry really started to work seriously on the 
development of a new generation of peptide-based therapeutics, prompted by advances in the understanding 
of the genetics of disease. But initial enthusiasm was soon dampened by the realisation that drug delivery 
technologies at that time were not up to the task of getting these relatively large compounds into the body 
effectively, while production could be complex and expensive. 
Now, with drug delivery seeing enormous strides forward, the stage seems to be set for a renaissance in 
peptide drugs. 
A just-published report by Frost & Sullivan notes that the global therapeutic peptides market is currently 
valued at around $1 billion (€756m), with Europe contributing about $300m of that total, and will at around 
10.5 per cent a year between 2003 and 2010. This means that the European market for peptides will double in 
size by 2010 to $605m. 
"The rising need for new therapeutic approaches combined with the potential of peptides as active 
pharmaceutical ingredients (APIs) for effective drug formulation is contributing to rapid market de velopmen t, " 
says the report. But it cautions that manufacturers will need to show they can scale-up their production 
process to meet demand. 
One driver behind the resurgent interest ln peptides has been the development of large synthetic and biological 
peptide libraries that, in combinatlon with hlgh-throughput screening processes, has enhanced the prospects of 
obtaining new drug candidates, according to the author of the report, F&S research analyst Himanshu Parmar. 
The approval of new peptide-based drug products such as Roche's HIV treatment Fuzeon (enfuvirtide) is 
stirring interest among many pharmaceutical companies. Globally, more than 40 peptide-based products are 
commercially available with six in the registration process. In Europe, about four to six peptide based products 
are ln the market, with 100 in the clinlcal stage and 150 in advanced preclinical phases. 
Peptides used in drug formulation and clinical trials account for nearly 93 per cent of the European therapeutic 
peptides market with R&D comprising the remainder. Almost 60 per cent of the market comprises peptide-
based therapeutics for the oncology segment followed by cardiovascular, infection and metabolic therapeutics. 
Despite the significant progress that has been made, technological challenges relating to the effective delivery 
of peptides, their instability in vivo and short half-life remain critical challenges. Costly and inefficient large-
scale manufacturing and purification processes are, moreover, hampering market growth; Fuzeon itself has a 
massive 106 separate synthesis steps in its production, which has contributed to the hefty priee tag for the 
drug. 
The F&S report notes that prioritles ln research are to optimise peptide delivery inside cells, tissue organs or 
body, develop synthetic peptides with Increased stability and half life and realising peptidomimetic molecules 
that duplicate the structural and functional properties of biologically active peptides but are smaller and easier 
to work with. 
Meanwhile, it suggests that the development of cost-competitive, bulk manufacturing strategies are the key to 
sustained market expansion. "Modern and sophisticated formulàtion techniques, efficient and cost-effective 
scale up process and cutting-edge purification and separation methods with low cost and high throughput are 
fundamental to achieving high quality, economical products for commercial purposes," said Parmar. 
Bachem is currently the leading manufacturer ln the European therapeutic peptides market followed by UCB, 
PolyPeptide Laboratories, Peptisyntha and Diosynth. But other manufacturers are getting into the marketplace, 
including large chemical players like Clariant which recently started offering peptide manufacturing through an 
alliance with Indian company Jupiter Bioscience. 
But escalating priee sensitivity, competition and eroding priees are confronting ail European manufactures. And 
as in the wider API sector, intensifying competition from low-cost Asian manufacturers by 2006-2007 is 
expected to trigger further priee attrition ln the peptide category. 
"While manufacturers unable to compete on pricing will not be successful, they will also need to focus on 
competitive criteria such as quality, flexibility, reliability and implementation timeline," warned Parmar. 
"Additional strategies could inc/ude investing in process improvements, building manufacturing plants in low-
cost areas, improving product and service portfolios to build customer loyalty and entering into strategie 
alliances with manufacturers and pharmaceutical companies. " 
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